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A NOVEL PHOSPHORYLATION SITE IN THE TELOMERIC PROTEIN TRF2 IS
REGULATED BY THE ATR KINASE AND PLAYS A ROLE IN RELIEVING
REPLICATION STRESS AT THE TELOMERE

Kristina Hoke, Ph.D.
The Rockefeller University 2008

Phosphatidyl inositol 3-kinase-like kinases (PIKKs) have a well documented
function at yeast telomeres. Although several lines of evidence suggest that
members of the PIKK family also play a role in vertebrate telomere biology, little
is known about their specific functions. We report that the human shelterin
component, TRF2, overexpressed in 293T cells, is phosphorylated on serine 368
(S368) in a caffeine and wortmannin sensitive manner. Phosphorylation is
induced by hydroxyurea (HU) and ultraviolet (UV) radiation but not Ionizing
Radiation (IR). Knockdown studies indicate that ATR is the primary kinase
responsible for TRF2 S368 phosphorylation, while the mTOR kinase is implicated
as a negative regulator of the phosphorylation event. In order to study the
function of phosphorylation of TRF2 on S368, we replaced endogenous TRF2 in
MEFs with TRF2 containing mutated S368 (S366 in mouse). TRF2 S366
mutants fulfilled the major telomeric protective functions of TRF2 and prevented
cell cycle arrest, formation of telomere dysfunction induced foci, overhang loss,
telomere fusions, and telomere sister chromatid exchanges. TRF2 S368 mutants

were able to influence telomere length homeostasis in certain settings in both
human and mouse cells. In mouse cells, expression of TRF2 containing a
phosphomimetic mutation at position 366 (S366E) caused dramatic telomere
lengthening; in human cells, overexpression of S368 mutants did not reproduce
the rapid telomere shortening caused by overexpression of wildtype TRF2,
indicating that these mutants may not be able to promote t-loop HR. Telomeres
exhibited an unusual sensitivity to aphidicolin: 25-28% of 53BP1 foci induced by
aphidicolin treatment colocalized with telomeric DNA. Expression of TRF2
S366E improved survival of MEFs after aphidicolin treatment. Cells expressing
TRF2 S366E also exhibited fewer chromatid breaks and 53BP1 foci after
aphidicolin treatment, and the percentage of 53BP1 foci which colocalized with
telomeres was decreased by a small but significant amount. Finally, we show
that a phosphomimetic mutation at position 368 weakens the interaction between
TRF2 and TIN2, suggesting that phosphorylation of TRF2 on S368 may relieve
replication stress at the telomere by modifying the conformation of shelterin to
allow the replication fork to more easily pass.
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Chapter 1: Introduction

CHROMOSOME STRUCTURE AND REPLICATION
Most prokaryotic genomes consist of a single circular chromosome, while
the larger and more complex genomes of eukaryotes are usually composed of
multiple linear chromosomes. Linear chromosomes contain a single centromere,
which range from approximately 100 base pairs in budding yeast to several
megabases in humans1. Centromeres are composed of specialized chromatin
that forms the basis for the assembly of kinetochores, the points at which spindle
microtubules attach1. Centromeres generally consist of short tandem DNA
repeats, the sequences of which are not well conserved across species, however
mammalian centromeric chromatin contains a centromere-specific variant of
histone H3, distinguishing it from bulk chromatin2.
Chromosomes are chiefly replicated by conventional semi-conservative
DNA replication. Replication of chromosomal DNA begins when the Origin
Replication Complex (ORC) binds to an origin of replication and recruits the
machinery required for DNA replication3. Several thousand origins of replication
have been identified in S. cerevisiae, but identification of mammalian origins has
been much more difficult, and less than 20 veritable origins are defined3. At the
ends of linear chromomsomes, the mechanisms of DNA replication predict that
the lagging strand will be incompletely replicated due to the requirement for an
RNA primer, a predicament dubbed the ‘end replication problem’4,5. A second
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problem presented by linear chromosomes is the constituitive presence of DNA
ends in the nucleus. Because DNA ends normally indicate the occurrence of
double-stranded DNA breaks (DSBs) and cells have stringent mechanisms to
detect and respond to their presence, the DNA damage response machinery
must be able to distinguish chromosome ends from DSBs. Telomeres,
nucleoprotein structures located at the tips of the linear chromosome, mitigate
the end replication problem and prevent chromosome ends from being detected
as DNA damage.

TELOMERE STRUCTURE
Telomeres consist of GC-rich DNA repeats bound by specific proteins.
Vertebrate telomeres are composed of multiple repeats of the 6 nucleotide
sequence 5’-TTAGGG-3’. The sequence of most eukaryotic telomere repeats is
similar or the same as the vertebrate telomere repeat sequence. For example,
the hypotrichous ciliate telomere repeat is 5’-TTTTGGGG-3’6, the flowering plant

Arabidopsis thaliana telomere repeat is 5’-TTTAGGGG-3’7, and the silkworm
Bombyx mori telomere repeat is 5’-TTAGG-3’8.
Human telomeric tracts are 5-15 kb in length9 10. In the laboratory mouse,

Mus musculus, telomeric tracts are much longer, often greater than 30 kb.
However, the telomeres of Mus spretus and several other species of mouse are
closer in length to human telomeres, in the range of 4-12 kb, indicating that
significant interspecies variability in telomere length is possible, at least in
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rodents11 12. At the very end of the eukaryotic telomere, the G rich strand
protrudes past the terminus of the C rich strand to form a structure called the Gtail or G-overhang13. In humans the vast majority of C rich telomeric strands end
with the sequence 3’-ATC-5’ suggesting that the processing of the C strand
terminus is tightly regulated14. In contrast, the terminus of the G rich telomeric
strand is much less precise but the termini, 5’-GGTTAG-3’’, 5’-GGGTTA-3’’, or 5’AGGGTT-3’’ occur with higher frequency than the other possible permutations14.
T-loops, lariat-like DNA structures in which the 3’ overhang of the telomere
strand invades a more proximal portion of the double-stranded telomere can form
at chromosome termini15 16. T-loops have been documented at the telomeres of
humans, mice, chickens, trypanosomes, and the hypotrichous ciliate Oxytricha

fallax15 17 18 19, suggesting that they may be a near-universal feature of
chromosome termini. The resemblance of the t-loop to a DNA recombination
intermediate15 raises the possibility that the homologous recombination (HR)
machinery may be involved in their formation20 and that tight regulation of HR
may be required at the telomere to prevent unscheduled resolution of these
structures21.
The presence of nucleosomes has been demonstrated at the telomeres of
both vertebrates and invertebrates22 23 18. However, several observations indicate
that telomeric chromatin has different properties than bulk chromatin. The
telomeric mononucleosome is hypersensitive to micrococcal nuclease and the
linker of telomeric nucleosomes is minimal22 23 24. Also, the micrococcal nuclease
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digestion pattern of human telomeres in cells with short telomeres is more diffuse
than that of bulk chromatin, suggesting the presence of nucleosome free regions
or altered chromatin structures24.

TELOMERASE AND DISEASE

Telomerase
An activity that adds telomere repeats to GT-rich primers was identified in
the ciliate Tetrahymena25. The enzyme responsible for this activity, telomerase,
contains an RNA component26 called hTR, or hTERC in humans27, and a protein
component with reverse transcriptase activity,26 28 29 30 hTERT in humans31 32 (Fig
1-1). In budding yeast, the core components of telomerase associate with
several accessory proteins including Est1 which is involved in telomerase
recruitment33 34. Three putative human homologs of Est1 have been recently
identified, two of which associate with telomerase35 36. Recent biochemical
purification showed that catalytically active human telomerase consists of two
molecules each of hTERT, hTR, and the H/ACA box binding protein dyskerin37.
Telomerase must act to counter the terminal sequence loss due to the end
replication problem and active degradation of the telomere. Evidence that
telomeres are subject to active degradation comes from the observation that in
human and mouse cells lacking telomerase, telomeres shorten at a rate of 50150 bp/end/cell division, rather than the 3-5 bp/end/cell division predicted by the
end replication problem38.
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Figure 1-1: Human telomerase.
Catalytically active human telomerase consists of two molecules each of the reverse transcriptase hTERT,
the RNA template hTERC, and the ribonucleoprotein dyskerin. The accessory proteins Est1A and Est1B
may be involved in regulating telomerase recruitment and activity.

Senescence
Primary human fibroblasts grown in culture eventually stop dividing39, a
phenomenon known as replicative senescence. Telomeres shorten as
fibroblasts age10 and yeast with a mutation causing their telomeres to
progressively shorten enter a senescence-like state33. These observations led to
the proposal that replicative senescence is regulated by telomere shortening.
Replicative senescence was definitively linked to telomere shortening when it
was shown that introduction of hTERT into telomerase-negative cells causes
telomere elongation and cellular immortalization40.

Disease states related to telomerase function
The implications of telomere-mediated replicative senescence for cancer
and aging were readily identified41. In humans, telomerase activity is low in
somatic cells after embryonic development, with the exception of highly
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proliferative cells such as bone marrow cells42. However, most cancer cells have
regained telomerase expression43 and most of those that have not use a
recombination-based mechanism called Alternative Lengthening of Telomeres
(ALT)44 to lengthen their telomeres and circumvent telomere-mediated replicative
senescence.
Genetic models as well as human disorders have highlighted the
importance of telomere-mediated replicative senescence in human health. Late
generation mice that lack the telomerase RNA component are susceptible to
spontaneous malignancies, have shortened lifespans, and exhibit phenotypes
related to limited cell proliferative capacity such as poor wound-healing45 46 47 48.
Accumulating evidence indicates that the symptoms of the premature aging and
cancer susceptibility disease, Werner Syndrome, are due to telomere dysfunction
49 50 51 52

. The human disease, dyskeratosis congenita (DC), characterized chiefly

by skin abnormalities and bone marrow failure53, is caused by mutations in the
RNA component of telomerase54 or in dyskerin, a ribonucleoprotein that binds
and contributes to the maturational processing of hTERC55 and is a component of
catalytically active telomerase37. The phenotypes of DC can be attributed to
defective telomere maintenance, limiting the proliferative capacity of skin and
blood cells56. Mutations in the RNA component of telomerase can also lead to a
life-threatening form of anemia57 presumably by limiting the proliferative capacity
of the bone marrow.
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TELOMERE BINDING PROTEINS

The Shelterin Complex
In humans, chromosome ends are protected and regulated by the
shelterin complex, which is made up of six proteins that localize primarily to the
telomere and whose primary function is telomeric: TRF1, TRF2, Rap1, TIN2,
TPP1, and Pot158 (Fig. 1-2A). Shelterin is anchored to the double-stranded
TTAGGG repeats by TRF1 and TRF259 60 61 62 63. TRF1 and TRF2 are linked
together by TIN264,65, which also binds and recruits TPP1 to the telomere66 67.
TPP1 binds POT168 66 67, which can bind single-stranded telomeric DNA69 70. All
six components of shelterin can be found in a single complex64 71 but evidence
suggests that TRF1 and TRF2, and their direct binding partners, can exist in
separate complexes as well64,72.
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Figure 1-2: The Shelterin Complex
(A) Schematic of the shelterin complex on telomeric DNA. Human telomeres are protected and shaped by
shelterin, a complex of six proteins which localize primarily to the telomere and whose primary function is
telomeric.
(B) Domain structure of shelterin components. Interactions among shelterin components are indicated.
Interactions between shelterin components and telomeric DNA repeats are indicated by diagonal lines.
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TRF1
The first human telomeric protein to be discovered, TRF1, was isolated
from nuclear extracts based on its ability to bind telomeric DNA59. TRF1 is an
essential gene; its genetic deletion results in early embryonic lethality in the
mouse73. TRF1 has an N terminal acidic domain, a homodimerization domain, a
flexible domain, and a C terminal DNA binding domain containing myb-related
motifs60 61. TRF1 binds double-stranded telomeric DNA as a dimer and both myb
domains of dimeric TRF1 are required for DNA binding61. However there is no
constraint on distance or orientation for the telomeric binding sites of the two
DNA-binding domains of a TRF1 dimer74.
TRF1 overexpression in the tumor cell line HT1080, results in telomere
shortening while expression of a dominant negative allele of TRF1, which
removes endogenous TRF1 from telomeres, causes telomeres to lengthen75.
TRF1 affects the telomerase pathway; when TRF1 is overexpressed in
telomerase-negative primary human fibroblasts it has no effect on telomere
dynamics76.

TRF2
TRF2 was identified in the database based on its homology with TRF160 62.
The TRFH domains, which mediate homodimerization of TRF1 and TRF2, are
very closely related. However, heterodimerization between TRF1 and TRF2
does not occur60. The crystal structures of the TRFH domains shows that
differences at key residues sterically hinder formation of heterodimers between
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TRF1 and TRF277. Furthermore, the composition of potential protein interaction
surfaces, not involved in the dimer interface, differs significantly between TRF1
and TRF2, raising the possibility that these surfaces mediate interaction with
different factors77.
A striking difference between TRF1 and TRF2 is that while the N-terminal
50 amino acids of TRF1 are highly acidic, the corresponding region of TRF2 is
very basic. The flexible or “hinge” domains, which lie between the TRFH and
myb domains, are also quite different60, raising the possibility that these regions
are involved in the functional differences between TRF1 and TRF2. The crystal
structures of the TRFH domains revealed that the alpha helices forming an
individual TRFH domain fold back on each other so that the N and C terminus
are located near each other in space77, potentially positioning the N-terminal
acidic and basic domains of TRF1 and TRF2 respectively in close proximity to
the more C terminal hinge and DNA binding domains of the TRF proteins.
TRF2 can influence telomere length in telomerase negative cells and is
required to prevent telomeres from being recognized as DNA damage. These
functions of TRF2 will be discussed in detail below.

Rap1
The TRF2 interacting protein Rap1 was found in a two-hybrid screen using
TRF2 as bait78. The telomeric localization of Rap1 is dependent on TRF278 and
in the absence of TRF2, Rap1 is destabilized79. Human Rap1 contains an Nterminal BRCT domain, central myb domains, and a RCT (Rap1 C Terminus)
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domain as do the Rap1 orthologs of S. cerevisiae and S. pombe78.
Overexpression studies indicate that human Rap1 is a negative regulator of
telomere length and also suggest that the BRCT domain of Rap1 influences
telomere length homogeneity80. Whether Rap1 contributes to telomere end
protection is currently unknown81. Unlike human Rap1, S. cerevisiae Rap1 binds
directly to telomeric DNA82 using its myb domains83.
Like human Rap1, S. pombe Rap184 and S. cerevisiae Rap185 are negative
regulators of telomere length. In S. cerevisiae, the Rap1 ortholog localizes to
multiple sites in the genome in addition to telomeres and regulates the silencing
of mating type loci and the transcription of several promoters86.

TIN2
TIN2 was first identified as a TRF1 interacting factor involved in
telomerase dependent telomere length regulation87. More recently it was shown
that TIN2 can bind TRF1 and TRF2 simultaneously, and disruption of this
interaction results in decreased telomeric TRF1 and TRF2, and a DNA damage
response at telomeres65 64. The C terminus of TIN2 binds TRF1 within the TRFH
domain87, while the N terminus of TIN2 binds TRF265. The crystal structure of
the interaction between TIN2 and TRF1 was recently solved, revealing that
amino acids 256-276 of TIN2 bind the loop region between alpha helices 3 and 4
of the TRF1 TRFH domain (Chen et al., in prep.). Surprisingly, in spite of the
similarity of the TRFH domains of TRF1 and TRF2, the TRFH domain of TRF2 is
not used for TIN2 binding, and a short region within the flexible hinge region
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(amino acids 352-357) is required instead (Chen et al., in prep.). TIN2 also binds
TPP1 and is required for its localization to the telomere66 67 88. Therefore TIN2
can influence the telomeric localization of all shelterin components. The link
between TRF1 and TRF2 provided by TIN2 stabilizes both proteins and their
binding partners at the telomere. TIN2 is also required for the telomeric
localization of TPP1 which recruits the single-stranded telomeric binding protein
Pot1 to the telomere.

TPP1/POT1
The telomeres of the hypotrichous ciliate Oxytricha nova are bound by
Telomere End Binding Proteins alpha and beta (TEBPα and TEBPβ)89 90. The
crystal structure of TEBPα and TEBPβ in complex with telomeric DNA shows
these proteins use three oligonucleotide/oligosaccharide–binding folds (OB folds)
to bind the single-stranded telomeric DNA and a fourth to interact with each
other91.
Homology with the N-terminus of TEBPα led to the identification of a
single-stranded telomeric DNA binding protein in S. pombe69. This TEBPα
ortholog was named Pot1 (Protection of Telomeres) because its deletion causes
immediate degradation of telomeres with all surviving cells having completely
circularized chromosomes69.
On the basis of homology with S. pombe Pot1, human Pot1 was also
identified69. The N-terminal OB fold of human Pot1 is required for binding of
single-stranded telomeric DNA70 however a mutant lacking this region, Pot1ΔOB,
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still localizes to telomeres and causes rapid telomere elongation by preventing
TRF1-mediated inhibition of telomerase92. In addition to playing a role in
telomere length regulation in human cells, Pot1 also functions in telomere
protection, described in more detail below.
Both human Pot1 and mouse Pot1a and Pot1b require interaction with the
shelterin component TPP1 to localize to telomeres68 66 67. Structural and
functional data indicate that the TPP1/POT1 complex is the evolutionary
equivalent of O. nova TEBPα and TEBPβ68 93 94.

TELOMERE PROTECTION BY TRF2

TRF2 prevents telomeres from activating the DNA damage response machinery
The consequences of TRF2 removal suggest that telomeres lacking TRF2
are perceived by the cell as DNA damage. TRF2 was initially inhibited by
expression of a mutant form of TRF2 lacking both the N-terminal basic domain
and the DNA binding myb domain, TRF2ΔBΔM, which acts as a dominant negative
allele and removes TRF2 from telomeres63. When TRF2 is inhibited, many of the
same proteins which localize to DSBs, are detectable at telomeres. These
telomeric foci, named Telomere Dysfunction Induced Foci (TIFs) contain DNA
damage response factors including 53BP1, phosphorylated histone H2AX
(γH2AX), ATM phosphorylated on S1981, Mre11, Nbs1, and phosphorylated
Rad1795 96 79. Underscoring their similarity to the DNA damage foci which form at
DSBs, the efficient formation of TIFs after TRF2 inhibition requires the ATM
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checkpoint kinase95 96 97. The ATM kinase is required for the appropriate cellular
response to DSBs induced by ionizing radiation, including the formation of γH2AX
foci at sites of damage98 activation and stabilization of p5399 100, and initiation of
cell cycle checkpoints101.
Growth arrest induced by inhibition of TRF2 led to a senescence-like
phenotype in IMR90 primary fibroblasts and HTC75 fibrosarcoma cells63 and
apoptosis in several cell types including HeLa cells, primary T cells, and
immortalized B cells102. Again paralleling the cellular response to DSBs,
apoptosis in response to inhibition of TRF2 requires functional p53 and ATM102.
Inhibition of TRF2 in primary fibroblasts induces a form of senescence
which shares many characteristics with replicative senescence: expression of
senescence-associated β-galactosidase, stabilization of p53, induction of p21,
hypophosphorylation of Rb, and induction of p16103. Overexpression of TRF2
can also affect the induction of senescence. TRF2 overexpression causes
primary fibroblasts to senesce with shorter telomeres than control cells with
normal levels of TRF2104. One interpretation of these results is that induction of
replicative senescence is not simply dictated by telomere length, but rather by the
amount of TRF2 present at each chromosome end.

TRF2 protects telomeres from non-homologous end-joining
Telomere fusions resulting from TRF2 inhibition are dependent on DNA
Ligase IV and Ku indicating that they are generated by non-homologous end
joining (NHEJ)105 79 106. When telomeres fuse due to inhibition of TRF2, the
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double-stranded part of the telomere remains largely intact and is detectable at
sites of fusion, however the single stranded telomeric overhang is degraded63 by
the NER endonuclease ERCC1/XPF in human cells107. Removal of the 3’
overhang is expected to be a prerequisite for the joining of telomeres by NHEJ105.
The S. pombe TRF1 and TRF2 ortholog, Taz1, also protects telomeres from
NHEJ-mediated telomere fusion108.

TRF2 protects telomeres from Homologous Recombination
TRF2 overexpression results in telomere shortening76,104. Unlike TRF1,
TRF2-induced telomere shortening can occur in the absence of telomerase109 104.
The rapid telomere shortening observed when TRF2 is overexpressed may be
due to the homologous recombination (HR) machinery acting on t-loops, in a
process called t-loop HR. T-loop HR was proposed to explain the phenotype of
overexpression of an allele of TRF2 which lacks the N-terminal Basic domain but
retains the myb domain and localizes to telomeres, TRF2ΔB. TRF2ΔB protects
telomeres from NHEJ, but leads to telomere shortening and the formation of tloop sized extrachromosomal telomeric circles21. As t-loops resemble an
intermediate of homologous recombination and the phenotype of TRF2ΔB was
dependent on the Rad51 paralog, XRCC3, it was proposed that the telomeric
deletions induced by TRF2ΔB expression are due to the HR machinery acting on tloops21. In yeast, a similar mechanism may explain the phenomena of Telomere
Rapid Deletion (TRD) in which up to several kb of DNA are rapidly lost from
telomeres110 111.
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TRF2 also acts in parallel with the NHEJ factor Ku to prevent homologous
recombination between telomeres on sister chromatids, called Telomere Sister
Chromatid Exchange (T-SCE)106. Loss of either TRF2 or Ku alone does not lead
to increased rates of T-SCE, but combined loss of both proteins results in T-SCE
at approximately 15% of chromosome ends106. The rapid deletion or elongation
of individual telomeres caused by T-SCE could potentially lead to telomere
dysfunction and telomere length deregulation. Evidence that a third form of HR
threatens telomeric integrity was seen in cells that lack the Nucleotide Excision
Repair factor ERCC1/XPF, which interacts with TRF2. ERCC1/XPF null MEFS
contain a high frequency of Telomeric DNA-containing double minute
chromosomes, structures which may result from a recombination event between
telomeres and chromosome internal TTAGGG repeats107.
The TRF ortholog Taz1 also seems to negatively regulate HR at
telomeres, as a form of telomere elongation that is dependent on HR can only
occur in the absence of Taz1112. Interestingly, a protein whose primary function
is thought to be in homologous recombination, the Rad51 paralog, Rad51D, has
been detected at telomeres and its absence leads to telomere shortening and
telomere fusions113. Similarly, mouse cells without Rad54 have shorter telomeres
and more frequent telomere fusions than wildtype controls, although this protein
has not yet been detected at telomeres114. Taken together, these data indicate
that while HR related processes are important for the normal functioning of
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telomeres, possibly by facilitating the formation of t-loops, they must be tightly
regulated, probably by TRF2, to protect the integrity of telomeres.

Potential mechanisms for TRF2-mediated telomere protection
TRF2 may contribute to the protection of telomeres in several different
ways. TRF2 promotes the formation of t-loops, structures in which the 3’
overhang of the telomere is literally hidden by strand invading the doublestranded part of the telomere15 16. TRF2 may also supplement the protection of
telomeres provided by t-loops by binding and preventing the activation of the
ATM kinase115. Karlseder et al. 115 observed that cells in which TRF2 is highly
overexpressed do not respond appropriately to IR induced DNA damage. IR
primarily activates the checkpoint kinase ATM, and several read-outs of ATM
activation after IR are blunted in TRF2 overexpressing cells. These include
stabilization of p53 and induction of its downstream targets p21, Bax, and Hdm2.
Nbs1 phosphorylation on S343, a target of ATM, was also dampened in the
presence of high levels of TRF2. Additionally, cells overexpressing TRF2 bypass
the IR induced G2/M checkpoint at higher rates than control cells. Furthermore,
it was shown that ATM and TRF2 interact by co-immunoprecipitation115, allowing
the possibility that TRF2 directly inhibits ATM through a physical interaction. The
idea that a high local concentration of TRF2 at the telomere could inhibit the
activation of the ATM kinase is consistent with the observation that signaling from
DSBs induced near chromosome internal telomeric repeats is inhibited116.
Telomeric deprotection upon loss of TRF2 could also be related to the

17

concomitant removal of its shelterin binding partners from telomeres, TIN2 and
Rap1. The relative contribution of these non-mutually exclusive mechanisms for
telomere protection by TRF2 is currently being explored.

TELOMERE PROTECTION BY POT1
RNAi-mediated inhibition of Pot1 in human cells leads to TIF formation in
G1 and causes the 5’ terminus of the telomere, which normally ends on the
sequence 3’ATC5’, to end on a random nucleotide within the 3’AATCCC5’ repeat117.
In mouse, both Pot1a and Pot1b contribute to the protection of telomeres, but
loss of Pot1a causes a more severe telomere deprotection phenotype than loss
of Pot1b118. Like TRF2, Pot1a and Pot1b act in parallel with Ku to prevent TSCE; increased levels of T-SCE are seen in MEFs which are triply deficient in
Pot1a, Pot1b, and Ku (Palm and de Lange, in prep.). Interestingly, loss of Pot1b
but not Pot1a causes a marked increase in the single-stranded telomeric
overhang, suggesting Pot1b may be involved in regulating exonucleolytic
degradation of the C-rich telomere strand118.
While the DNA damage response to removal of TRF2 from telomeres is
chiefly dependent on the checkpoint kinase ATM, damage signaling after Pot1
removal requires the checkpoint kinase ATR97. ATR, and its binding partner
ATRIP, are recruited to ssDNA bound by RPA119, suggesting a model wherein the
damage signal elicited by Pot1 removal is initiated by RPA binding to telomeric
single-stranded DNA that would normally be bound by Pot1.
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SHELTERIN ASSOCIATED FACTORS AND THEIR ROLE AT TELOMERES

TRF1 associated factors
The poly (ADP-ribose) polymerase, tankyrase, was identified in a yeast-2hybrid screen using TRF1 as bait120. Tankyrase localizes to telomeres and ADPribosylation of TRF1 by tankyrase reduces TRF1 binding to telomeric DNA120.
Overexpression of tankyrase causes telomere elongation121 while its inhibition
results in telomere shortening122. Tankyrase binds its partners using a conserved
motif found in human TRF1 but not mouse TRF1123, and tankyrase does not
appear to be involved in telomere length regulation in mouse122. TRF1 may also
negatively regulate telomere length through its interaction with PINX1, a protein
that can inhibit telomerase in vitro124. However, the PINX1 homolog of S.

cerevisiae, Gno1p, is involved in ribosomal RNA maturation but does not affect
telomere length125.

TRF2 associated factors
In addition to its binding partners Rap1 and TIN2, which are members of
the shelterin complex, TRF2 interacts with several other factors which have
prominent non-telomeric functions, many of which are involved in DNA
metabolism. In spite of the role of TRF2 in preventing the NHEJ of telomeres,
TRF2 interacts with the NHEJ proteins Ku and DNA-PKcs126 127 128. The Mre11
complex, composed of Mre11, Rad50, and Nbs1, was found in TRF2
immunoprecipitates129. Nbs1 is only present at telomeres during S phase while
Mre11 and Rad50 are present throughout the cell cycle129. Patients with
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Nijmegen Breakage Syndrome (NBS) lack normal Nbs1 function and exhibit
chromosome instability, cancer susceptibility, immunodeficiency, and
radiosensitivity130 131. Fibroblasts from NBS patients exhibit shorter telomeres
than fibroblasts of roughly the same passage from unaffected individuals132. The
telomere length defect of NBS fibroblasts is rescued by expression of hTERT and
Nbs1 together, but not by either protein alone132, suggesting that the Mre11
complex is involved in the telomerase pathway. ATM and Mre11 function
interdependently in the response to DSBs133 134 135 and recent evidence suggests
that ATM and MRN may also collaborate to regulate telomere length in human
cells136. The Nucleotide Excision Repair Endonuclease ERCC1/XPF
immunoprecipitates with TRF2 and is required for the removal of the 3’ telomeric
overhang after TRF2 inhibition in human cells107. As discussed above,
ERCC1/XPF may also contribute to the prevention of homologous recombination
between telomeres and chromosome internal telomeric repeats107.
TRF2 also interacts with the RecQ helicases WRN and BLM and can
stimulate their helicase activity on substrates resembling telomeric DNA137 138.
RecQ helicases are believed to facilitate replication fork progression by disrupting
obstructing DNA structures, including G quadruplex DNA, and may also play a
role in the reinitiation of replication after fork collapse139. Impaired WRN function
has deleterious consequences for telomeres that may be related to problems
during telomere replication. Overexpression of a dominant negative WRN allele
results in loss of lagging strand telomeres52. Late generation MEFs that are
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doubly deficient for WRN and telomerase exhibit frequent sister telomere
exchanges, one potential outcome of replication fork collapse within a
telomere140. Additionally, primary fibroblasts which lack WRN function undergo
premature senescence which can be reversed by expression of telomerase49.
TRF2 was recently shown to interact with Apollo, a nuclease related to
Artemis. Apollo localizes to telomeres and its knockdown results in senescence
and TIF formation primarily in S phase141 142. An unusual phenotype observed
when Apollo is inhibited is an increased frequency of telomere ends with two or
more telomere signals141, the significance of which is currently unknown. The Cterminus of Apollo binds the loop region between alpha helices 3 and 4 of the
TRFH domain of TRF2 (Chen et al., in prep.).

REGULATION OF TELOMERASE BY SHELTERIN
A negative feedback mechanism that regulates telomere length in human
cells was identified by overexpression of the shelterin component TRF1.
Overexpression of TRF1 in the telomerase positive tumor cell line HT1080
causes telomeres to shorten despite unaltered telomerase activity75. The amount
of TRF1 present at telomeres is proportional to telomere length76 92 and TRF1 has
no effect on telomerase activity in vitro76 indicating that TRF1 is acting in cis at
telomere ends to block telomerase action. More recently it was shown that the
negative regulation of telomere length by TRF1 is mediated by Pot192. A similar
negative feedback mechanism appears to function in yeast, with Rap1 as the cis-
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acting negative regulator of telomerase in S. cerevisiae85 and Taz1 performing a
similar role in S. pombe143.
Telomerase must also be recruited to telomere ends, the importance of
which was highlighted by a recent study showing that only 20-50 molecules of
telomerase are present in the nuclei of human 293T cells37. In order for such a
small number of molecules to localize to their rare substrate, the 3’ overhang of
telomeres, a powerful recruitment mechanism must exist. In mammals, recent
evidence indicates that the shelterin component TPP1, which functions in the
negative regulation of telomerase action by recruiting Pot1 to the telomere66 67, is
also involved in the recruitment and activation of telomerase94 93.

RECOMBINATION-BASED MAINTENANCE OF TELOMERE LENGTH
Mammalian telomeres can be maintained in the absence of telomerase by
a process known as Alternative Lengthening of Telomeres (ALT)144. Cells that
maintain their telomeres using the ALT pathway have longer and more
heterogeneous telomeres than related non-ALT cells145 44 146. By tagging
telomeres with a specific DNA sequence, it was shown that a high level of
intertelomeric recombinational events occur in ALT cells147. Cells that employ the
ALT mechanism contain ALT-associated PML bodies (APBs) that contain
telomeric DNA, TRF1, TRF2, and a number of proteins involved in DNA
replication and recombination148 144. Most cancer cells that have not activated
telomerase expression employ ALT to lengthen their telomeres44.
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PIKKs AND TELOMERES
The mammalian phosphatidyl inositol 3-kinase-like kinase (PIKK) family
includes ATM, ATR, DNA-PKcs, mTOR, SMG1, and the catalytically inactive
TRRAP149. ATM, ATR, and DNA-PKcs have distinct but overlapping roles in
maintaining genome integrity. ATM and ATR are the primary activators of the
DNA damage response, phosphorylating multiple targets leading to cell cycle
checkpoint activation and DNA repair150. While ATM and ATR can phosphorylate
many of the same substrates including p53, Nbs1, and Rad17151, they are
activated by different types of DNA damage. Double-stranded DNA breaks
(DSBs) are the most well characterized activator of ATM152, while DNA damage
related to replication stress primarily activates ATR153. Interestingly, ATM can be
activated downstream of ATR in response to replication stress154 and conversely,
ATR can be activated in response to DSBs in an ATM dependent manner155 156 157
158

. DNA-PKcs is largely dispensable for the signaling of DNA damage; in its

absence, DNA damage checkpoints and downstream read-outs of the DNA
damage response, such as phosphorylation and stabilization of p53, are intact159.
However, DNA-PKcs and its binding partners, Ku70 and Ku86, are involved in the
NHEJ-mediated DNA repair of double-stranded DNA breaks160.
SMG1 was identified as the human ortholog of a C. elegans gene,
involved in Nonsense-mediated mRNA Decay (NMD)161. In addition to its role in
NMD, eliminating mRNAs containing premature stop codons, SMG1 is also
involved in the maintenance of genome integrity. Cells deficient in SMG1 exhibit
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increased sensitivity to IR, are unable to optimally phosphorylate and stabilize
p53 in response to DNA damage, and exhibit evidence of spontaneous DNA
damage in the form of foci of histone variant H2AX phosphorylated on serine 139
(γH2AX) and constituitive Chk2 phosphorylation162. mTOR, unlike other members
of the PIKK family, is not directly implicated in the maintenance of genome
integrity. Rather, it is involved in the complex regulation of cell growth in
response to nutrient availability163.
In yeast, PIKKs also play a role at telomeres. S. cerevisiae Tel1 and Tel2
were identified in an early screen for genes required for the maintenance of
telomere length164. Tel1 is the yeast ortholog of the ATM kinase, however until
recently the function of Tel2 was obscure. Data indicating that Tel2 is a master
regulator of PIKK stability, and therefore required for Tel1 function, explains the
requirement of Tel2 for telomere length maintenance (Takai et al., in press). In

S. cerevisiae, Tel1 and Mec1 have been detected at telomeres165 and Tel1
preferentially associates with the shortest telomeres166 167 168. In both S.

cerevisiae and S. pombe Tel1 and Mec1 (Rad3 in S. pombe) are required for the
maintenance of telomere length169 170 171. Tel1 and Mec1 could influence telomere
length by phosphorylating factors involved in telomerase recruitment. Tel1 and
Mec1 can phosphorylate Cdc13 within its telomerase recruitment domain, and
mutation of these sites leads to telomere shortening172 and Tel1 (but not Mec1) is
required for the recruitment of telomerase components Est1p and Est2p in late
S/G2173.
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Mre11 complex components are also required for telomere length
maintenance, however deletion of Mre11 complex components in Tel1 deficient
strains causes no additional telomere length defect indicating that Tel1 and the
Mre11 complex function in the same pathway to regulate telomere length174 175, a
relationship that may be analogous to their partnership in the signaling of DSBs133
134 135

. The preferential association of Tel1 with the shortest telomeres requires

the S. cerevisiae Nbs1 ortholog Xrs2166 167 168. Recent data also suggests that
ATM and the Mre11 complex may be involved in TRF1 mediated telomere length
control in humans136. Intriguingly, HR mediated deletion of t-loops induced by
expression of the mutant allele of TRF2, TRF2ΔB, requires Nbs121, suggesting that
the Mre11 complex may be involved in this non-telomerase based mechanism of
telomere length regulation.
As discussed above, ATM and ATR are involved in the signaling of
dysfunctional telomeres, consistent with their role in the maintenance of genome
integrity102 97 95 96 176. Although the role of PIKKs in the normal physiology of
telomeres has not been well studied, some evidence suggests that members of
this family are involved in telomere length regulation and protection in mammals.
The disease Ataxia Telangiectasia (AT), in which ATM function is lost, is
characterized by neurological deterioration, immunodeficiency, and cancer
susceptibility177 178. The telomeres from cells of AT patients were reported to be
shorter than age matched controls179, however this study examined telomere
length in lymphocytes, which proliferate in response to infection, making it likely
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that the shortened telomeres observed in these cells was secondary to the higher
frequency of infection in AT patients. However, in cultured cells, overexpression
of truncated forms of ATM shorten telomeres180 suggesting that ATM function
may be able to directly influence telomere length. Additionally, telomerase
deficient mice have shorter telomeres at earlier generations when DNA-PK is
also absent181. A mild telomere deprotection phenotype has been observed in
mice lacking DNA-PK182 183 and Ku184. Recently it was shown that human cells
lacking one allele of Ku86 exhibit telomere shortening and increased telomeric
fusions185. However, TIF formation was not observed in Ku knockout MEFs,
indicating that Ku is not required to protect telomeres in mouse106. Although a
telomeric function of the SMG1 kinase has not been reported, a link between the
NMD pathway and telomere biology was recently established when the NMD
protein SMG-6 (Est1A) was shown to be the human homolog of the S. cerevisiae
telomeric protein Est1, and found to associate with telomerase and play a role in
telomere capping35 36.

REPLICATION OF TELOMERIC DNA
Telomeric DNA presents several theoretical obstacles to the efficient
passage of the replication fork. The G-rich strand of telomeric DNA can form
quadruplex structures under certain conditions186, which present an obvious
obstacle to the passage of the replication fork187. Repeats can also lead to the
formation of other unusual structures, such as H-DNA and “sticky” DNA, and also

26

may cause polymerase slippage188. Furthermore, telomere-specific DNA binding
proteins might hinder the passage of the replication fork, such is the case with
the well-studied E. coli Tus protein189.
Several lines of evidence indicate that replication fork progression through
telomeric DNA is hindered. Telomeric DNA is a poor substrate in the in vitro
replication system of linear SV40 DNA190 and EM analysis of synthetic model
replication forks consisting of telomeric DNA show frequent fork regression, often
resulting in four-stranded chickenfoot structures191. In vivo, replication forks
proceed slowly through telomeric DNA in S. cerevisiae192 193. In human cells
synchronized with aphidicolin, BrdU incorporation into telomeric DNA occurs in
two distinct phases during S phase, consistent with replication fork stalling during
passage through telomeric DNA20.
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Chapter 2: TRF2 can inhibit ATM autophosphorylation

INTRODUCTION
When TRF2 is removed from telomeres, chromosome ends activate a
DNA damage response that is dependent on the checkpoint kinase ATM102 95 97.
TRF2 could mediate the inhibition of ATM at telomeres through several, nonmutually exclusive mechanisms. TRF2 may modify the chromosome terminus so
that it does not resemble a DNA end, possibly by promoting the formation of tloops - structures in which the 3’ telomeric overhang is tucked into a more
proximal duplex region of the telomere15 16. Secondly, it is possible that ATM
activation upon TRF2 inhibition is actually due to the concomitant removal of the
shelterin binding partners of TRF2; when TRF2 is genetically removed from
mouse cells, Rap1 protein is reduced to nearly undetectable amounts79 and TIN2
levels at the telomere drop by over 50%68. A final possibility is that TRF2 inhibits
ATM activation directly.
Direct inhibition of ATM activation by TRF2 is supported by the finding that
TRF2 and ATM physically interact115. Immunoprecipitation of ATM from primary
human fibroblasts results in recovery of approximately 1% of endogenous TRF2.
The veracity of this interaction is underscored by the finding that anti-ATM
immunoprecipitates from fibroblasts that lack functional ATM do not contain
TRF2, even when TRF2 is overexpressed. In co-immunoprecipitation
experiments using purified baculovirus derived TRF2 and GST-tagged ATM

28

fragments, TRF2 bound two fragments of ATM spanning amino acids 1439 –
2138. This region contains the FAT (FRAP, ATM, TRAPP) domian, conserved in
PIKKs, and the S1981 autophosphorylation site, discussed below.
Further supporting the hypothesis that TRF2 itself prevents activation of
ATM, is the finding that ATM is not appropriately activated by ionizing radiation in
cells expressing high levels of TRF2115. TRF2 overexpression blunts read-outs of
ATM activation after IR, including phosphorylation and stabilization of p53 and
induction of its downstream targets p21, Bax, and Hdm2. Nbs1 phosphorylation
on S343, a target of ATM, was also diminished after IR in the presence of high
levels of TRF2. Additionally, cells overexpressing TRF2 bypass the IR induced
G2/M checkpoint at higher rates than control cells.
Autophosphorylation on S1981 was identified as a crucial event in ATM
activation194. By exposing untreated fibroblasts to the cross-linking agent
formaldehyde, it was shown that ATM normally exists as a dimer or higher order
multimer. DNA damage leads to the dissociation of multimeric ATM into
monomers, the active form of the kinase. Autophosphorylation on S1981 is
detectable as early as 30 seconds after IR194, and was shown to be crucial for the
dissociation of multimeric ATM into its active, monomeric form, and subsequent
ATM dependent signaling events194.
Recently, controversy has arisen regarding whether autophosphorylation
on S1981 is required for ATM activation. In vitro, ATM S1981 mutants were
activated by DNA ends and the MRN complex as well as wildtype ATM134.
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Furthermore, in contrast to what was observed in human cells, mutation of the
pertinent autophosphorylation site (S1987) in murine ATM did not affect its
function195. Transgenic mice were generated that express ATM containing S1987
mutated to alanine (S1987A) on a BAC and these were backcrossed with ATM-/mice to generate animals which only express ATM with the S1987A mutation.
These transgenic mice develop normally and their cells exhibit normal cell cycle
arrest and phosphorylation of ATM substrates after treatment with IR195.
Furthermore, the mutant form of ATM localizes to DNA breaks195. The
importance of the autophosphorylation event for the activation of ATM may be
different in human and mouse, a view supported by the recent report that human
ATM S1981 mutants localize to DSBs caused by the endonuclease PpoI196.
Importantly, three additional ATM autophosphorylation sites have been
discovered which are required for proper ATM signaling in response to DNA
damage197. Regardless of whether autophosphorylation on S1981 is a
requirement or a consequence of ATM activation, it serves as an early indicator
of ATM activity, and is currently the most reliable method for detecting activation
of ATM itself.
To determine whether TRF2 affects ATM signaling by acting on ATM
itself or by acting at a point downstream of ATM in the signaling pathway, we
examined the effect of TRF2 overexpression on autophosphorylation of ATM on
S1981. The ability of TRF2 to influence ATM signaling could signify a hitherto
unknown function of TRF2 in the DNA damage response. We address this
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question by determining whether TRF2 relocates from telomeres to sites of DNA
damage.

RESULTS
In order to study the effect of TRF2 overexpression on the IR induced
autophosphorylation of ATM on S1981, ATM and TRF2, TRF1, or the empty
plasmid vector were expressed by transient transfection in 293T cells.
Expression of TRF2 by transient transfection in 293T cells was utilized because
extremely high levels of overexpression can be achieved in this setting. ATM
phosphorylation on S1981 can be detected after IR doses as small as 0.1 Gy and
phosphorylation is maximal after treatment with 0.4 Gy IR194. In order to obtain a
dose-dependent increase of ATM phosphorylation in response to IR, transfected
293T cells were exposed to 0, 0.3, or 0.6 Gy IR. ATM activation was monitored
by western blotting with an antibody against ATM phosphorylated on S1981194,
here called αATM-P. ATM phosphorylation was robustly induced by IR in vector
transfected control cells. In comparison, TRF2 overexpressing cells exhibited
lower levels of phosphorylated ATM after IR (Fig. 2-1A). Western blot signals
were quantified by densitometry. The relative level of ATM phosphorylated on
S1981 (normalized to total ATM protein) at 0.3 Gy was 49% of the vector control
value (p = 0.002, Student's t test; n = 7). ATM phosphorylation was not blunted
in cells overexpressing another telomeric protein, TRF1, indicating that the effect
is specific to TRF2. Overexpression of TRF2 also diminished the IR-induced ATM
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autophosphorylation of endogenous ATM in IMR90 fibroblasts to 55% of vector
control value at 0.3 Gy and 60% of vector control value at 0.6 Gy (Fig. 2-1B).
In order to elucidate the mechanism by which overexpressed TRF2
inhibits ATM, we attempted to analyze the effect of TRF2 on dissociation of the
multimeric ATM complex induced by IR. However, we were unable to detect
evidence of the ATM multimer by treating unperturbed cells with formaldehyde,
precluding us from analyzing the effect of TRF2 on the dissociation of this
complex.
To determine if the N-terminal basic domain, which is involved in the
protection of telomeres from HR, is involved in the inhibition of ATM activation by
TRF2, we expressed an allele of TRF2 lacking the N terminal basic domain,
TRF2ΔB, in 293T cells by transient transfection. Surprisingly we found that
expression of TRF2ΔB resulted in significant destabilization of co-transfected ATM
protein, preventing us from determining the effect of this allele on ATM activation.
These results raise the issue of whether TRF2 has a hitherto unknown
role, modulating ATM activation after DNA damage, as has been proposed198. If
this were the case, TRF2 would be predicted to localize to IR induced foci, where
it would be in a position to influence ATM activation. However, it has previously
been shown that endogenous TRF2 remains at telomeres and does not localize
to IR induced foci129. We tested whether overexpressed TRF2 could be detected
at such foci, and found that, likewise, it was not (Fig. 2-1C).
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Figure 2-1: TRF2 inhibits activation of ATM by Ionizing Radiation.
(A) Overexpression of TRF2 inhibits IR-induced phosphorylation of transfected ATM in 293T cells. 293T
cells co-transfected with ATM and either TRF2, TRF1, or vector were treated with the indicated doses of
IR. After a 30 min. recovery, cells were harvested and western blot analysis was performed on whole-cell
lysates.
(B) Overexpression of TRF2 inhibits IR-induced phosphorylation of endogenous ATM in primary
fibroblasts. IMR90 primary fibroblasts infected with a retroviral construct expressing TRF2 or an empty
virus were treated with the indicated doses of IR. After a 1 hr recovery, cells were harvested and ATM was
immunoprecipitated from whole-cell lysates. Western blot analysis was performed on immunoprecipitated
ATM.
(C) Overexpressed TRF2 does not localize to IRIFS. IMR90 primary fibroblasts infected with a retroviral
construct expressing TRF2 were treated with 5 Gy IR. After a 90 min recovery, cells were fixed and
processed for immunofluorescence with or without Triton X-100 extraction before fixation. Arrowheads
denote foci of TRF2 signal previously demonstrated to represent telomeres. When overexpressed, some
TRF2 is localized to nucleolus.
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DISCUSSION
We have demonstrated that ATM autophosphorylation on S1981 after IR
is inhibited by overexpression of TRF2. However, in our hands, TRF2, even
when overexpressed, does not localize to IR induced foci, where it would be in a
position to modulate ATM activation. Several other lines of evidence indicate that
TRF2 is not normally involved in the response to DSBs. Importantly, TRF2
knock-out MEFs are proficient at NHEJ, repairing uncapped telomeres using this
pathway79. HR also appears to be unimpeded in the absence of TRF2 as
frequent telomere sister chromatid exchange occurs in cells that lack TRF2 and
the NHEJ protein Ku106. Furthermore, both ATM and ATR signaling are active in
MEFs after TRF2 has been deleted79 97. Because TRF2 does not play an obvious
role in the normal response to DSBs, we surmise that the effect on ATM
activation reflects an activity of TRF2 that is usually only employed at telomeres.
In our transfection experiments, ATM was inhibited by extremely high levels of
TRF2, at least 20-fold higher than the endogenous protein. Under the conditions
used in these experiments, TRF2 was present not just at telomeres, but also at
high levels throughout the nucleus115. Normally, TRF2 localizes primarily to the
telomere, and thus would be able to act locally, preventing ATM from becoming
active only near the chromosome end.
TRF2, as a member of the shelterin complex, prevents telomeres from
being recognized as DSBs58. One way shelterin may function in this capacity is
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by the formation of t-loops, hiding the single stranded overhang through a strand
invasion in a proximal region of the double-stranded telomere15 16. However,
even within the proposed t-loop, there are DNA structures that are predicted to
activate a DNA damage response including ss-ds transitions, 3’ and 5’ ends, and
single-stranded DNA. Preventing these structures from activating the DNA
damage response may be achieved by direct inhibition of ATM by TRF2. We
considered a model whereby TRF2, which is a dimer, would bind ATM dimers
and prevent their dissociation, a step proposed to be crucial for ATM activation
by Bakkenist and Kastan194. However, we were unable to determine whether
TRF2 affects the dissociation of multimeric ATM in response to DNA damage,
and currently the mechanism by which TRF2 inhibits ATM activation is unknown.
For the reasons discussed above, we have interpreted our data about the
effect of TRF2 overexpression on ATM activation to represent a function of TRF2
that would normally be carried out at the telomere. Other groups have reached a
different conclusion. Bradshaw et al.198 show that TRF2 localizes to DNA
damage induced by a high intensity laser. They go on to show that
overexpression of TRF2 inhibits ATM S1981 phosphorylation and several
downstream read-outs of ATM activity, essentially reproducing the results of
Karlseder et al. Bradshaw et al. conclude that TRF2 has a non-telomeric function
in the DNA damage response. The discrepancy regarding whether TRF2
localizes to sites of damage is probably due to the method Bradshaw et al. used
to generate DNA damage, laser microbeam irradiation. The authors themselves
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estimate that the laser microbeam produces DNA damage equivalent to
approximately 80 Gy IR or 2800 DSBs per nucleus. This amount of DNA
damage is clearly supraphysiological. ATM activation, as measured by S1981
phosphorylation, is detectable after 0.1 Gy IR (about 4 DSBs per nucleus) and
maximal after 0.4 Gy194. The immense amount of damage created by the laser
must cause a correspondingly supraphysiologic recruitment of DNA damage
response factors. Because TRF2 is a known binding partner of many DNA
damage response factors including the MRN complex129, ERCC1/XPF107, and
WRN138 137, it may be simply dragged along in the laser-induced DNA damage
response tsunami. Another possible explanation for the discrepancy is raised by
the finding that a mutant form of TRF2 lacking the N terminal basic domain,
TRF2ΔB, does not localize to laser induced damage198. The basic domain of
TRF2 was recently shown to interact with DNA structures in a sequenceindependent manner199 200 with a preference for three and four-way DNA junctions
resembling those found in replication forks and homologous recombination
intermediates200. These findings raise the possibility that the observed
localization of TRF2 to laser induced DNA damage is a result of a non-specific
interaction between the basic domain of TRF2 and unusual DNA structures
induced by the laser.
Recently, a second study confirmed that TRF2 is recruited to high intensity
laser induced damage, but also showed that TRF2 does not localize to DSBs
produced by more conventional lower intensity lasers or IR from a Cs137
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source201. These results indicate that the localization of TRF2 to DNA damage
induced by the high intensity laser is due to the unique quality and magnitude of
this type of DNA damage, and that TRF2 does not localize to DNA damage in
biologically relevant settings201.

37

Chapter 3: A novel TRF2 phosphorylation site is regulated by PI3Klike protein kinases

INTRODUCTION
The mammalian phosphatidyl inositol 3-kinase-like kinase (PIKK) family
includes ATM, ATR, DNA-PKcs, mTOR, SMG1, and the catalytically inactive
TRRAP149. ATM, ATR, and DNA-PKcs have distinct but overlapping roles in
maintaining genome integrity. ATM and ATR are the primary activators of the
DNA damage response, phosphorylating multiple targets leading to cell cycle
checkpoint activation and DNA repair150. While ATM and ATR can phosphorylate
many of the same substrates including p53, Nbs1, and Rad17151, they are
activated by different types of DNA damage. Double-stranded DNA breaks
(DSBs) are the most well characterized activator of ATM152, while DNA damage
related to replication stress primarily activates ATR153. Interestingly, ATM can be
activated downstream of ATR in response to replication stress154 and conversely,
ATR can be activated in response to DSBs in an ATM dependent manner155 156 157
158

. DNA-PKcs is largely dispensable for the signaling of DNA damage; in its

absence, DNA damage checkpoints and downstream read-outs of the DNA
damage response, such as phosphorylation and stabilization of p53, are intact159.
However, DNA-PKcs and its binding partners, Ku70 and Ku86, are involved in
the NHEJ-mediated DNA repair of double-stranded DNA breaks160.
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SMG1 was identified as the human ortholog of a C. elegans gene involved
in Nonsense-mediated mRNA Decay (NMD)161. In addition to its role in NMD,
eliminating mRNAs containing premature stop codons, SMG1 is also involved in
the maintenance of genome integrity. Cells deficient in SMG1 exhibit increased
sensitivity to IR, are unable to optimally phosphorylate and stabilize p53 in
response to DNA damage, and exhibit evidence of spontaneous DNA damage in
the form of γH2AX foci and constitutive Chk2 phosphorylation162. mTOR, unlike
other members of the PIKK family, is not directly implicated in the maintenance of
genome integrity. Rather, it is involved in the complex regulation of cell growth in
response to nutrient availability163.
In yeast, PIKKs also play a role at telomeres. S. cerevisiae Tel1 and
Mec1 (orthologs of ATM and ATR, respectively) are present at telomeres in a
cell-cycle dependent manner165 and are involved in telomere length regulation169.
Similarly, in the fission yeast S. pombe, Tel1 and the Mec1 homolog, Rad3, are
required for maintenance of telomere length170 171.
Consistent with their role in the DNA damage response, ATM and ATR are
involved in the signaling of dysfunctional telomeres102 97 95 176 96. Although the role
of PIKKs in the normal physiology of telomeres has not been well studied, some
evidence suggests that members of this family are involved in mammalian
telomere length regulation179 180 181 and telomere protection182 184 183. Although a
telomeric function for the SMG1 kinase has not been reported, a link between the
NMD pathway and telomere biology was recently established when the NMD
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protein SMG-6 was shown to be the human homolog of the S. cerevisiae
telomeric protein EST1A, and found to associate with telomerase and play a role
in telomere capping35 36.
The only known requirement for PIKK phosphorylation is a serine or
threonine followed by a glutamine (SQ or TQ)151 202. Many PIKK kinase targets
have SQ/TQ motifs in groups known as SQ/TQ Cluster Domains (SCD)203. One
example of a SCD containing protein is the S. cerevisiae telomere binding protein
Cdc13, which has 10 SQ/TQ motifs in two clusters, and can be phosphorylated in

vitro by Tel1 and Mec1172. The functional consequences of SQ/TQ
phosphorylation are generally thought to include effects on protein-protein
interactions. For example, ATR phosphorylates histone H2AX on S139 in
response to replication stress204 and ATM and DNA-PK do the same in response
to DSBs98 205 206. The BRCT tandem domain of MDC1 specifically binds
phosphorylated S139 of H2AX, and this interaction is required for the efficient
recruitment of DNA damage response proteins to sites of damaged chromatin207.
Several telomeric proteins have conserved SQ/TQ motifs. TRF1 has a
conserved SQ site at amino acids 219-220 (within the dimerization domain),
which can be phosphorylated by ATM208. Human TRF2 has three SQ/TQ motifs,
T188, S368, and S380. S380 is not conserved in mouse, T188 is conserved in
mammals but not all vertebrates, and S368 is found in all known vertebrate TRF2
proteins (Fig. 3-1). Recently it was reported that TRF2 is phosphorylated on
T188 in response to IR209. We report that TRF2 can be phosphorylated on S368,
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and show that this phosphorylation is both positively and negatively regulated by
PIKKs. In the course of our studies, we document that antibodies targeting
phosphorylated SQ/TQ residues within specific proteins, have a proclivity to
cross-react with phosphoproteins other than their intended targets.

Figure 3-1: Conserved SQ/TQ motifs in the telomeric protein TRF2.
Schematic of human TRF2. The positions of conserved SQ/TQ motifs and minimal binding domains for
TRF2 binding partners Rap1 and TIN2 are indicated. Relevant TRF2 sequences from the indicated
organisms surrounding the conserved TQ and SQ motifs were aligned with ClustalW. Boxes indicate
identical amino acids. The conserved TQ and SQ motifs are shaded in pink. The TQ motif at amino acids
188/189 is conserved in mammals, but not vertebrates. The SQ motif at amino acids 368/369 is conserved
in vertebrates.
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RESULTS

Human TRF2 is phosphorylated on S368 when expressed by transient
transfection in 293T cells
As described in Chapter 2, TRF2 was overexpressed in 293T cells by
transient transfection to determine its effect on the activation of ATM by IR. ATM
activation was monitored by western blotting with a phosphospecific antibody
against ATM phosphorylated on S1981, αATM-P. When TRF2 was
overexpressed, but not a vector control or another protein such as TRF1, a
strong band was evident on the αATM-P western blot that co-migrated with
overexpressed TRF2 (Fig 3-2A). Examination of the amino acid sequence of
TRF2 revealed that amino acids 361-375 were very similar to the peptide used to
generate αATM-P (Fig 3-2B). Amino acids 361-375 are 57.1% identical and
64.3% similar to the ATM peptide. The pertinent serine at position 368 in human
TRF2 is extremely well conserved, present in all known vertebrate TRF2 proteins
(Fig. 3-1). In contrast, the only other conserved SQ/TQ motif in TRF2 (T188) is
present in mammals but not in zebrafish or chicken. S368 is located in the
flexible hinge domain of TRF2, and lies immediately adjacent to the minimal
binding domain required for interaction between TIN2 and TRF2.
In order to determine if αATM-P was truly detecting TRF2
phosphorylated on S368, the serine was mutated to a glycine and this construct
was expressed in 293T cells by transient transfection. Cells containing this
mutant form of TRF2 did not exhibit a band with the MW of TRF2 on the αATM-P
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western (Fig 3-2C). In order to confirm that the band represented TRF2
phosphorylated on S368, overexpressed TRF2 was immunoprecipitated from
293T cells and treated with lambda phosphatase (Fig. 3-2D). Phosphatase
treatment abolished TRF2 reactivity with αATM-P. Highly concentrated purified
human TRF2 produced in insect cells using the baculovirus expression system
did not react with αATM-P on western blot, indicating that TRF2 is not
phosphorylated on S368 in this setting and that αATM-P cannot detect TRF2 that
is not phosphorylated on S368 by western blot, even when it is highly abundant
(Fig. 3-2E). Taken together, these data indicate that the αATM-P antibody is
detecting a veritable phosphorylation event on serine 368 of TRF2
overexpressed in 293T cells.
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Figure 3-2: TRF2 expressed in 293T cells by transient transfection is phosphorylated on serine 368.
(A) αATM-P detects a band that co-migrates with TRF2 when TRF2 is expressed in 293T cells by transient
transfection. Myc-tagged wildtype human TRF2 or TRF1, or the plasmid vector were expressed in 293T
cells by transient transfection. 48 hrs. after transfection, cells were treated with low doses of IR, allowed to
recover for 1 hr., and harvested.
(B) The peptide used to generate αATM-P (underlined) is highly similar to amino acids 361-375 of human
TRF2. Identical amino acids are indicated.
(C) αATM-P does not detect TRF2 transiently expressed in 293T cells when S368 has been mutated to a
neutral residue. Wildtype TRF2 (wtTRF2), TRF2 containing glycine at position 368 instead of serine
(TRF2S>G) or the empty vector were expressed in 293T cells by transient transfection. A non-specific
band detected by αATM-P serves as a loading control.
(D) Myc-tagged wildtype TRF2 expressed in 293T cells by transient transfection was immunoprecipitated
using a polyclonal rabbit antibody against TRF2 (647) and treated with lambda phosphatase. A nonspecific band detected by αATM-P serves as a loading control.
(E) TRF2 protein produced in insect cells using baculovirus is not detectable by αATM-P. Increasing
amounts of TRF2 protein were analyzed by western blotting with antibody 647 to detect TRF2 and αATMP to detect TRF2 phosphorylated on S368.
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TRF2 S368 phosphorylation is positively regulated by ATR, and negatively
regulated by mTOR
Because TRF2 S368 precedes a glutamine (Q), it represents a potential
PIKK target. Furthermore, because the region surrounding TRF2 S368 so
closely resembles the region surrounding ATM S1981, a site of
autophosphorylation, it seemed likely that the kinase(s) responsible for TRF2
S368 phosphorylation were members of the PIKK family. Because ATM
activation is inhibited in the context of TRF2 overexpression in 293T cells (Fig. 21), ATM seemed an unlikely candidate for positively regulating S368
phosphorylation in this setting.
In order to determine whether members of the PIKK family promoted
phosphorylation of TRF2 on S368, 293T cells transfected with wildtype TRF2
were treated with the PIKK inhibitors caffeine and wortmannin. TRF2 S368
phosphorylation levels were monitored by western blot with the αATM-P antibody
(Fig. 3-3A). Caffeine and wortmannin both severely reduced TRF2
phosphorylation on S368 when used at concentrations shown to inhibit ATM,
ATR, and DNA-PK. Notably, when wortmannin was used at a lower
concentration, 0.3 µM, known to inhibit ATM and DNA-PK but not ATR210, it did
not affect the level of S368 phosphorylation (Fig. 3-3A).
To help pinpoint the identity of the PIKK kinase(s) involved in TRF2 S368
phosphorylation, 293T cells transfected with wildtype TRF2 were treated with
either IR to activate ATM or UV radiation to activate ATR, and allowed to recover
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for 1 hr. before harvesting. TRF2 S368 phosphorylation levels were again
monitored by western blot with the αATM-P antibody. While 5 Gy IR strongly
induced ATM S1981 phosphorylation, visible in the same blot, TRF2 S368
phosphorylation was not affected (Fig. 3-3B). In contrast, UV radiation increased
TRF2 S368 phosphorylation (Fig. 3-3B). UV-induced upregulation of TRF2
S368-P was evident as soon as 30 min. after UV (Fig. 3-3C), making it less likely
that ATM activation by UV is playing a role in the phosphorylation154. Induction of
TRF2 phosphorylation on S368 by UV radiation is repressed by caffeine
treatment (Fig. 3-3D) consistent with positive regulation by a PIKK. HU
treatment, which induces replication stress by depleting the deoxynucleotide
triphosphate pool, also increased TRF2 S368 phosphorylation (Fig. 3-3E).
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Figure 3-3: Phosphorylation of S368 on TRF2 expressed in 293T cells by transient transfection is
diminished by PIKK inhibitors and induced by UV radiation and HU, but not IR.
(A) The phosphorylation of S368 on TRF2 expressed by transient transfection in 293T cells is diminished
by the PIKK inhibitors caffeine and wortmannin. Myc-tagged wildtype TRF2 was expressed in 293T cells
by transient transfection. 48 hrs. after transfection, cells were treated with 10 mM caffeine, 0.3 µM
wortmannin, or 10 µM wortmannin for 4 hrs.
(B) Phosphorylation of S368 on TRF2 expressed in 293T cells by transient transfection is induced by UV
radiation, but not IR. Myc-tagged wildtype TRF2 was expressed in 293T cells by transient transfection. 48
hrs. after transfection, cells were exposed to 5 Gy IR or 40 J/m2 UV radiation. Cells were harvested 1 hr.
after treatment.
(C) Induction of phosphorylation of S368 on transfected TRF2 by UV radiation is detectable 30 min. after
treatment. Myc-tagged wildtype TRF2 was expressed in 293T cells by transient transfection. 48 hrs. after
transfection, cells were exposed to 40 J/m2 UV radiation, and allowed to recover for either 30 or 60 min.
before harvesting.
(D) Induction of phosphorylation of S368 on transfected TRF2 by UV radiation is inhibited by caffeine.
Myc-tagged wildtype TRF2 was expressed in 293T cells by transient transfection and exposed to 40 J/m2
UV radiation. Cells were harvested 1 hr. after treatment. Indicated samples were preincubated with 10
mM caffeine for 4 hrs.
(E) HU treatment increases levels of S368 phosphorylation of transfected TRF2, but does not induce
detectable levels of endogenous TRF2 phosphorylated on S368. 293T cells were transfected with myctagged wildtype TRF2 or an empty vector. 48 hrs. after transfection, cells were treated with 2 mM HU for
18 hrs.
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To determine whether the ATR kinase is responsible for the
phosphorylation of TRF2 on S368, an RNAi mediated knockdown approach was
used in 293T cells. Dharmacon ON-TARGETplus SMARTpool siRNA against
the ATR kinase was used to lower its expression. SMARTpool siRNA or control
siRNA and TRF2 were cotransfected into 293T cells using DharmaFECT Duo
transfection reagent. Nearly complete knockdown of ATR was achieved using
this strategy. ATR knockdown reproducibly led to diminished levels of TRF2
phosphorylated on S368 (Fig. 3-4A). shRNA-mediated knockdown of ATM (Fig.
3-4B) or DNA-PK (Fig. 3-4C) did not reduce levels of TRF2 phosphorylated on
S368. Attempts to knock down SMG1, with three distinct shRNA constructs (Fig.
3-4D), two distinct siRNA duplexes, and Dharmacon ON-TARGETplus
SMARTpool siRNA against SMG1, failed to achieve significantly reduced levels
of SMG1 protein. Therefore, we cannot exclude involvement of SMG1 in the
phosphorylation of TRF2 on S368.
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Figure 3-4: Knockdown of ATR, but not ATM or DNA-PK, reduces TRF2 phosphorylation on S368.
(A) siRNA-mediated knockdown of ATR reduces phosphorylation of transfected TRF2 on S368. 293T
cells were co-transfected with myc-tagged wildtype TRF2 and Smart Pool siRNA targeting ATR or a
control siRNA targeting luciferase. 48 hrs. after transfection, cells were harvested. Two independent
transfections are shown.
(B) shRNA-mediated knockdown of ATM does not reduce phosphorylation of transfected TRF2 on S368.
293T cells were infected with 3 different shRNA constructs (1-3) targeting ATM or a control shRNA
targeting luciferase. Subsequently, myc-tagged wildtype TRF2 was expressed by transient transfection. 48
hrs. after transfection, cells were harvested.
(C) shRNA-mediated knockdown of DNA-PK does not reduce phosphorylation of transfected TRF2 on
S368. 293T cells were infected with an shRNA construct targeting DNA-PK (DNA-PK sh #2, DNA-PK sh
#1 and sh#3 did not efficiently knockdown DNA-PK levels) or a control shRNA targeting luciferase.
Subsequently, myc-tagged wildtype TRF2 was expressed by transient transfection. 48 hrs. after
transfection, cells were harvested.
(D) shRNA mediated knockdown of SMG1 was not efficient. 293T cells were infected with 3 different
shRNA constructs targeting SMG1 (1-3) or a control shRNA targeting luciferase. Subsequently, myctagged wildtype TRF2 was expressed by transient transfection. 48 hrs. after transfection, cells were
harvested.
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Effects of mTOR signaling on the phosphorylation of TRF2 on S368
In order to determine whether mTOR plays a role in the regulation of TRF2
phosphorylation on S368, wildtype mTOR was co-transfected into 293T cells with
wildtype TRF2. Surprisingly, co-transfection of mTOR resulted in almost
complete abolition of phosphorylation of TRF2 on S368, while total TRF2 levels
were unaffected (Fig. 3-5A). Co-transfection of a second wildtype mTOR
construct in a different vector also severely diminished TRF2 phosphorylation on
S368, but a kinase-dead mTOR mutant did not (Fig. 3-5B).
If mTOR is a negative regulator of TRF2 phosphorylation on S368, TRF2
S368 phosphorylation should be inversely related to mTOR activity. The mTOR
kinase activity should be high at the time of 293T transfection, which is done
when cells are actively dividing. As the cells approach confluence, depletion of
nutrients in the media will be sensed by mTOR and mTOR activity will be
downregulated 211. In order to test the effect of cell proliferation on the
phosphorylation of TRF2 on S368, transfected 293T cells were monitored at 16
hr. intervals. mTOR activity was determined by phosphorylation of p70 S6
ribosomal kinase and p85 S6 ribosomal kinase, major mTOR targets. As
expected, mTOR activity was high at the time of transfection and was diminished
at later timepoints (Fig. 3-5C). Transfected TRF2 was already expressed at the
16 hr. timepoint, as determined by western blot with a myc antibody, but TRF2
phosphorylated on S368 was not detected until the 36 hr. time point, when
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mTOR activity was low (Fig. 3-5C). These data are consistent with an inverse
relationship between mTOR activity and TRF2 phosphorylation on S368.
To confirm that mTOR is a negative regulator of TRF2 phosphorylation on
S368, we treated 293T cells transfected with TRF2 with the well-characterized
mTOR inhibitor, rapamycin. Cells were subjected to rapamycin 12 hrs. after
transfection when mTOR activity is still high. Although phosphorylation of p70 S6
ribosomal kinase and p85 S6 ribosomal kinase were reduced after treatment with
10 nM rapamycin for 30 min., no significant change in the phosphorylation of
TRF2 on S368 occurred, even with concentrations as high as 50 nM (Fig. 3-5D).
The interpretation of the lack of a rapamycin effect is confounded by recent data
indicating that mammalian mTOR exists in two separate complexes, mTORC1
and mTORC2212. mTORC1 is rapamycin sensitive and performs the functions
typically ascribed to mTOR, regulation of cell growth in response to nutrient
availability. mTORC2 however, has a different set of binding partners, and is
rapamycin insensitive. Its function is more elusive, and while it shares some
functions of mTORC1, it positively regulates Akt/PKB while mTORC1 does not213,
214

and may play a role in regulating the cytoskeleton215 216. mTORC2 is generally

rapamycin insensitive, however it has now been shown that treating cells for
prolonged periods with rapamycin interferes with mTORC2 complex assembly
and results in reduced functional mTORC2217. In order to determine whether
mTORC2 plays a role in regulating TRF2 phosphorylation on S368, 293T cells
transfected with TRF2 were treated with 20 nM rapamycin for 24 hrs. In
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response to this treatment, a small but reproducible increase in TRF2
phosphorylation was observed, suggesting that mTORC2 may be a negative
regulator of TRF2 phosphorylation on S368.

Figure 3-5: Effects of mTOR signaling on phosphorylation of TRF2 on S368.
(A) Overexpression of wildtype mTOR drastically reduces S368 phosphorylation of transfected TRF2.
HA-tagged wildtype mTOR or an empty vector were co-transfected with myc-tagged wildtype TRF2 into
293T cells. 48 hrs. after transfection, cells were harvested.
(B) Overexpression of wildtype mTOR (different construct than in (A)) but not a kinase-dead allele,
reduces S368 phosphorylation of transfected TRF2. Flag-tagged wildtype mTOR or HA-tagged kinasedead mTOR were co-transfected with myc-tagged wildtype TRF2 into 293T cells. 48 hrs. after transfection,
cells were harvested.
(C) Post-transfection, phosphorylation of TRF2 on S368 inversely correlates with mTOR activity. 293T
cells were transfected with wildtype TRF2 and harvested at the indicated timepoints post-transfection.
Lysates were analyzed by western blotting with phospho-p70 S6 Kinase antibody (Cell Signaling) which
detects mTOR targets, p70 S6 kinase phosphorylated on T389 and p85 S6 kinase phosphorylated on T412
(asterisks).
(D) Rapamycin treatment for 30 min. does not affect S368 phosphorylation of transfected TRF2. Myctagged wildtype TRF2 was expressed in 293T cells by transient transfection. 48 hrs. after transfection,
cells were treated with the indicated doses of rapamycin for 30 min.
(E) Rapamycin treatment for 24 hrs. increases S368 phosphorylation of transfected TRF2. Myc-tagged
wildtype TRF2 was expressed in 293T cells by transient transfection. 24 hrs. after transfection, cells were
treated with 20 nM rapamycin for 24 hrs.
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Attempts to detect endogenous TRF2 phosphorylated on S368
Experiments described so far were performed in the setting of TRF2
expressed by transient transfection in 293T cells. Lysates from several different
human cell types were analyzed by western blot with the αATM-P antibody to
attempt to detect evidence of endogenous TRF2 phosphorylated on S368 (Fig. 36A). Endogenous TRF2 phosphorylated on S368 was not detected in the
telomerase-positive transformed cell lines, HeLa or HT1080. The
phosphorylation was likewise undetectable in BJ cells, non-telomerase
expressing primary foreskin fibroblasts. Some telomerase-negative cells
maintain their telomeres using the recombination-based ALT mechanism. Cells
that employ the ALT mechanism contain ALT-associated PML bodies (APBs)
that contain TRF1, TRF2, and a number of proteins involved in DNA replication
and recombination148. ATR kinase activity may be high in APBs, potentially
leading to detectable levels of TRF2 S368 phosphorylation. However, the
modification was undetectable in the ALT cell line GM847 (Fig. 3-6A).
The region surrounding S368 is highly conserved in mammals (Fig. 3-1).
In mouse TRF2 the phosphorylated residue predicted to be targeted by the
αATM-P antibody is serine 366. Lysates from MEFs and various mouse tissues
were analyzed by western blot with the αATM-P antibody for evidence of
endogenous TRF2 phosphorylated on S366, but the modification was
undetectable (Fig. 3-6B).
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The inability to detect endogenous TRF2 phosphorylated on S368 by
western blot with the αATM-P antibody suggests that the modification is present
at low abundance, possibly only during specific phases of the cell cycle. In
addition to being activated by DNA replication stress, the ATR pathway is
involved in unperturbed DNA replication218, and ATR has been detected at
telomeres during S phase after aphidicolin block20. In light of our data indicating
that ATR is a positive regular of TRF2 S368 phosphorylation, it seemed possible
that the modification could be an S phase specific event.
To address the possibility that phosphorylation of TRF2 on S368 was an
S-phase specific event, HeLa cells were blocked at the G1/S boundary by double
thymidine block. After release from block, samples for FACs and western blot
were taken at the indicated time points. TRF2 phosphorylated on S368 is not
detectable throughout the cell cycle, including at the 2 hr. time point when the
majority of cells are in S phase (Fig. 3-6C). We also employed centrifugal
elutriation, which fractionates cell cycle populations based on their sedimentation
rates. For each elutriation fraction, samples for western blot and FACs were
taken. Although FACs analysis determined that the elutriation process efficiently
fractionated cells according to cell cycle stage (Fig. 3-6D), TRF2 phosphorylated
on S368 was not detectable in any of the fractions (Fig. 3-6E).
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Figure 3-6: Attempts to detect endogenous TRF2 phosphorylated on S368 with αATM-P.
(A) Endogenous TRF2 phosphorylated on S368 is present at low or undetectable levels in several human
cell types.
(B) Endogenous TRF2 phosphorylated on S368 in MEFs and mouse meiotic tissues is undetectable by
western with αATM-P.
(C) Endogenous TRF2 phosphorylated on S368 is undetectable in cell-cycle specific samples from HeLa
cells synchronized by double thymidine block. Cells were released from thymidine block and harvested at
the indicated timepoints for western and FACs. FACs using PI determined the indicated phase of the cell
cycle for each sample.
(D) FACs analysis of elutriated HeLa cells. HeLa S3 (suspension cells) were fractionated according to
sedimentation properties using centrifugal elutriation. For each fraction, samples for western blot and
FACs were taken. FACs using PI determined the indicated phase of the cell cycle for each sample. Y axis,
cell numbers; x axis, relative DNA content on the basis of staining with propidium iodide.
(E) Endogenous TRF2 phosphorylated on S368 is undetectable in cell-cycle specific samples from HeLa
cells fractionated by centrifugal elutriation. A non-specific band on the anti-TRF2 western blot serves as a
loading control.
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Because of the observed increase of the phosphorylation of transfected
TRF2 in 293T cells after UV treatment and the finding that S368 phosphorylation
is positively regulated by ATR, induction of DNA replication stress was employed
in an attempt to increase S368 phosphorylation of endogenous TRF2 to
detectable levels. Treatment of HeLa cells and untransfected 293T cells with UV
did not result in detectable TRF2 S368 phosphorylation (Fig. 3-7A). As
previously shown, HU treatment increased S368 phosphorylation of transfected
TRF2, but did not induce detectable levels of endogenous TRF2 phosphorylated
on S368 (Fig. 3-3E, vector transfected cells).
ATR activation can also be achieved by exposing cells to the alkylating
agent methyl methanesulfonate 219 Untransfected 293T cells were treated with
0.02% MMS for four hrs. and subsequently analyzed by western blotting with the
αATM-P antibody. The αATM-P antibody detected several bands where
endogenous TRF2 is expected to run which were induced by MMS treatment
(Fig. 3-7B). However, our attempts to immunoprecipitate TRF2 after MMS
treatment to determine whether it was phosphorylated on S368 failed, so we
were unable to confirm the identity of these bands.
We asked whether ATR activation at telomeres might induce
phosphorylation of telomere bound TRF2 on S368. While removal of TRF2 from
telomeres predominately activates checkpoint kinase ATM, inhibition of POT1
function activates ATR97, possibly by exposing ssDNA which can be bound by
RPA. In mouse, POT1 function is shared by two genes, Pot1a and Pot1b, which
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have distinctive but overlapping roles in telomere end protection118. Cre was
expressed in cells conditionally null for either Pot1a (Pot1aF/-) or Pot1b (Pot1bF/-)
or both (Pot1a/b). Cells were harvested 96 hrs. after introduction of Cre, when
ATR activation as determined by Chk1 phosphorylation is robust97 and lysates
were analyzed by western blot with the αATM-P antibody. Although Pot1a/b
deletion induced a strong band of approximately 90 kDa on the αATM-P western
blot, endogenous TRF2 phosphorylated on S368 was not detectable (Fig. 3-7C).
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Figure 3-7: Attempts to detect endogenous TRF2 phosphorylated on S368 after induction of
replication stress.
(A) UV radiation of HeLa cells and untransfected 293T cells does not induce detectable levels of S368
phosphorylation of endogenous TRF2. Cells were treated with 40 J/m2 UV radiation and harvested 1 hr.
after treatment. A non-specific band on the αATM-P western blot serves as a loading control. Lysate from
293T cells transfected with myc-tagged wildtype TRF2 is included as a positive control for detection of
S368 phosphorylation.
(B) MMS treatment induces a band potentially representing endogenous TRF2 phosphorylated on S368.
293T cells transfected with myc-tagged wildtype TRF2 or a vector control were treated with 0.02% MMS
for 4 hrs.
(C) Pot1a and Pot1b removal does not induce detectable levels of endogenous TRF2 phosphorylated on
S368. MEFs conditionally null for either Pot1A (Pot1Af/-), Pot1B (Pot1BF/-) or both (Pot1a/b KO) were
treated with Cre. 96 hrs. after Cre induction, cells were harvested. Lysate from 293T cells transfected with
myc-tagged wildtype TRF2 is included as a positive control for detection of S368 phosphorylation.

We considered the possibility that the lack of detectable endogenous
TRF2 phosphorylated on S368 was due to phosphatase activity. In order to test
this, 293T cells transfected with wildtype TRF2 were treated with Okadaic Acid
(OA), a potent inhibitor of protein phosphatases type I (PP1) and 2A (PP2A)220.
As previously reported221, OA treatment significantly increases ATM
phosphorylation on S1981 (Fig. 3-8A). While OA did not increase total TRF2, a
slight increase in S368 phosphorylation of transfected TRF2 was observed (Fig.
3-8A). Untransfected 293T cells were also treated with 100 nM OA. Upon long
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exposure, the αATM-P antibody detects several bands that potentially co-migrate
with TRF2 (Fig. 3-8A). However, we were unable to confirm the identity of these
bands as our attempts to immunoprecipitate TRF2 after OA treatment to
determine whether it was phosphorylated on S368 failed. HeLa 1.3 cells were
also treated with increasing doses of OA. Although the αATM-P western blot
shows a dose dependent increase in ATM S1981 phosphorylation, no bands
potentially representing TRF2 phosphorylated on S368 were observed (Fig. 38A).
As discussed above, mTOR overexpression severely reduces S368
phosphorylation of TRF2 expressed in 293T cells by transient transfection,
suggesting that mTOR is a negative regulator of TRF2 S368 phosphorylation.
We postulated that inhibition of mTOR might increase the phosphorylation of
endogenous TRF2 to detectable levels. MEFs over-expressing wildtype TRF2
from a lentiviral vector were incubated with increasing doses of rapamycin,
however no bands potentially representing TRF2 phosphorylated on S368 were
induced on the αATM-P western (Fig. 3-8B). In the same cells, inhibition of
mTOR with rapamycin was combined with induction of replication stress by UV
treatment, but endogenous TRF2 phosphorylated on S368 was not detected (Fig.
3-8B). In conclusion, our inability to detect endogenous TRF2 phosphorylated on
S368 is most likely not due to inhibition of the phosphorylation by mTOR.

59

Figure 3-8: Attempts to induce detectable levels of phosphorylation of endogenous TRF2 on S368 by
inhibiting phosphatases with Okadaic Acid and mTOR with rapamycin.
(A) OA treatment induces a band potentially representing endogenous TRF2 phosphorylated on S368.
293T cells transfected with either wildtype myc-tagged TRF2 or the empty vector were treated with 100
nM Okadaic Acid (OA) for 3 hrs. HeLa 1.3 cells were treated with the indicated doses of OA for 3 hrs.
(B) MEFs expressing myc-tagged wildtype mouse TRF2 in a lentiviral vector were treated with 40 J/m2 of
UV radiation and allowed to recover for 1 hr. in the presence of the indicated dose of rapamycin.

Generating a specific antibody against TRF2 phosphorylated on S368
We argued that an antibody specific to TRF2 phosphorylated on S368
might improve our ability to detect the phosphorylation of endogenous TRF2.
The peptide used to generate the αATM-P is remarkably similar to the
corresponding region of TRF2, however they are not identical. Notably, TRF2
has the acidic residue aspartic acid (D) at S365 while ATM has the neutrally
charged glycine (G) at the corresponding residue, 1980 (Fig. 3-9A). Using the
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sequence surrounding TRF2 S368, we attempted to generate a phosphospecific
antibody that could detect TRF2 phosphorylated on S368 with higher sensitivity
and specificity than the αATM-P antibody. Amino acids 364-374 of human TRF2
are identical to the corresponding mouse residues (362-372) (Fig. 3-9A), so this
phosphopeptide was selected for rabbit immunization by the company AnaSpec,
San Jose, CA. The resulting antibody was affinity purified using the TRF2
phosphopeptide and affinity depleted with the non-phosphopeptide, to reduce
cross-reaction with the non-phosphorylated target.
The purified antibody, designated αTRF2S368-P, was tested for ability to
specifically detect TRF2 phosphorylated on S368 in western blots. Indicating
incomplete phosphospecificity, αTRF2S368-P detected a mutant form of TRF2
containing S368 mutated to glycine, albeit at much lower levels than it detected
wildtype TRF2 (Fig. 3-9B). As shown earlier, αATM-P does not cross-react with
this mutant form of TRF2 (Fig. 3-9B). Furthermore, no significant difference in
sensitivity between the two antibodies was observed. Because of its ability to
distinguish between phosphorylated and non-phosphorylated TRF2, the αATM-P
antibody was selected for future use detecting TRF2 phosphorylated on S368 by
western blot.
αATM-P detects ATM phosphorylated on S1981 by immunofluorescence
(IF)194 precluding us from using it to detect TRF2 phosphorylated on S368 by IF.
IF with αTRF2S368-P produced a nuclear granular staining pattern in HeLa cells,
and an occasional large focus of signal was observed (Fig. 3-9C). The granular
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staining pattern of αTRF2S368-P did not appear to be telomeric, and lack of
colocalization with TRF1 confirmed this (Fig. 3-9C). IF with αTRF2S368-P was
also performed in the cell line GM847, to determine if cells that maintain their
telomeres using ALT have detectable TRF2 phosphorylated on S368. In these
cells, αTRF2S368-P detected several large foci per cell that also stained
positively for PML, indicating that they are ALT-associated PML Bodies (APBs)
(Fig. 3-9D).
Because many SQ/TQ containing proteins involved in the DNA damage
response localize to APBs, it was possible that αTRF2S368-P could be crossreacting with another protein present in these structures. IR induced DNA
damage foci also contain many DNA damage response proteins that are
phosphorylated on SQ/TQ residues. However, it has previously been shown that
TRF2 does not localize to these foci (Fig. 2-1C,107) so αTRF2S368-P should not
be able to detect them. 53BP1 staining of HeLa cells subjected to 5 Gy IR
revealed the expected induction of foci. Surprisingly, co-staining with
αTRF2S368-P also revealed a strong induction of foci in response to IR that
colocalized with 53BP1 almost completely (Fig. 3-9E). Even in untreated cells,
αTRF2S368-P signal colocalizes with the occasional 53BP1 focus (Fig. 3-9E).
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Figure 3-9: Generation of an antibody to detect TRF2 phosphorylated on S368, αTRF2S368-P.
(A) Peptide used to generate an antibody to detect TRF2 phosphorylated on S368, αTRF2S368-P.
Alignment of the peptide used to generate αATM-P with amino acids 361-375 of human TRF2 and amino
acids 359-373 of mouse TRF2. Peptide used to generate αTRF2S368-P is underlined.
(B) αTRF2S368-P is incompletely phosphospecific for TRF2 phosphorylated on S368. Lysates of 293T
cells transiently transfected with either myc-tagged wildtype human TRF2 (wtTRF2), TRF2 containing
glycine at position S368 instead of serine (TRF2S>G), or the empty vector were analyzed by western blot
with αTRF2S368-P, αATM-P, and anti-TRF2 antibody (647). A non-specific band detected by αATM-P
serves as a loading control.
(C) αTRF2S368-P produces a nuclear granular pattern by IF which is not telomere specific. IF on HeLa
1.3 cells with the αTRF2S368-P and a mouse antibody against human TRF1.
(D) αTRF2S368-P detects ALT-associated PML bodies in GM847 ALT cells. IF was performed on
GM847 cells with αTRF2S368-P and an anti-PML antibody (Santa Cruz) to detect ALT-associated PML
bodies.
(E) αTRF2S368-P signal colocalizes with 53BP1 at IR induced DNA damage foci. HeLa 1.3 cells were
either untreated or subjected to 5 Gy IR. Cells were allowed to recover 1 hr. and fixed for IF. IF was
performed with αTRF2S368-P and an antibody for 53BP1 (gift of T. Halazonetis).
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To definitively determine that αTRF2S368-P detects a protein in DNA
damage foci other than TRF2, MEFs were employed in which one allele of TRF2
is deleted and the second allele is floxed, TRF2F/- 79. In TRF2F/- MEFs not
exposed to Cre, staining with αTRF2S368-P revealed a granular pattern, similar
to the staining pattern observed in HeLa cells (Fig. 3-10A). As we observed in
HeLa cells, the αTRF2S368-P signal occasionally showed foci in untreated cells
and these colocalized with γH2AX foci (Fig. 3-10A). Foci containing DNA
damage response proteins in cells that have not been subjected to DNA damage
have been observed previously and their function is unknown.
Cre treatment efficiently abrogated TRF2 protein (Fig. 3-10B). As
expected, Cre-mediated deletion of TRF2 results in robust TIF formation (Fig. 310C). As was observed after IR, αTRF2S368-P signal strongly colocalizes with
these DNA damage foci, even though these cells no longer contain detectable
levels of TRF2, indicating that this antibody detects a protein other than TRF2.
The extensive colocalization between the αTRF2S368-P signal and the
53BP1 signal observed in HeLa cells suggests that αTRF2S368-P may be
detecting 53BP1 itself, which contains many SQ/TQ motifs. Examination of the
amino acid sequence of 53BP1 revealed that the region surrounding Serine 25
was very similar to the peptide used to generate the αTRF2S368-P antibody (Fig.
3-10D). 53BP1 is phosphorylated on this residue in response to IR222. The high
degree of similarity between the region surrounding TRF2 S368 and the region
surrounding 53BP1 S25, and the extensive colocalization of signals, makes it
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likely that the αTRF2S368-P signal observed in IF is at least partly due to crossreaction with 53BP1 phosphorylated on S25.
However, signal resulting from αTRF2S368-P may be due to crossreaction with more than one protein. αATM-P detects a band of approximately
100 kDa, which is conspicuously up-regulated by HU and MMS treatment, as well
as Pot1a and Pot1b removal (Fig. 3-3E; 3-7B,C). This band represents another
interesting candidate for cross-reaction with αTRF2S368-P. To determine the
identity of this band, the amino acid sequences of proteins known to be involved
in the DNA damage response with MWs between 80 and 120 kDa were
examined. The 113 kDa protein MMS19 contains a region of striking similarity to
the peptide used to generate αTRF2S368-P (Fig. 3-10E). MMS19 is the human
homolog of S. cerevisiae Mms19, a protein involved in NER and RNA
polymerase II transcription223. 293T cells were treated with 0.02% MMS and
analyzed by western blot with αTRF2S368-P. As was seen with the αATM-P,
MMS treatment induced a band of approximately 100 kDa (Fig. 3-10F). An
antibody against hMMS19 (gift of J. Hoeijmakers) also detected a band of about
100 kDa. However, side by side comparison of western blots for MMS19 and
αTRF2S368-P show that the candidate band detected by αTRF2S368-P exhibits
a distinct electrophoretic mobility than the band detected by the MMS19 antibody
(Fig. 3-10F), suggesting that MMS19 is not the target of the antibody crossreactivity.
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Figure 3-10: α TRF2S368-P cross-reacts with another protein present in DNA damage foci.
(A) αTRF2S368-P produces a nuclear granular pattern in MEFs and colocalizes with occasional γH2AX
foci. TRF2F/- p53-/- MEFs (not exposed to Cre) were subjected to IF with αTRF2S368-P and an antibody
against Phospho-H2A.X (Ser139, γH2AX) (Upstate).
(B) Expression of Cre in TRF2F/- p53-/- MEFs depletes TRF2 protein. 120 hrs. after the introduction of Cre,
cells were harvested. Lysates were analyzed by western blot with an anti-TRF2 antibody (1254). Nonspecific bands detected by the antibody are indicated.
(C) αTRF2S368-P detects TIFs after TRF2 has been removed. TRF2F/- p53-/- MEFs were exposed to Cre.
120 hrs. after the introduction of Cre, cells were harvested. IF was performed with an antibody for γH2AX
and either an antibody for mouse TRF1 (644) or αTRF2S368-P.
(D) The peptide used to generate αTRF2S368-P is similar to 53BP1 amino acids 21-31.
(E) The peptide used to generate αTRF2S368-P is similar to a region of MMS19. Alignment of the peptide
used to generate αTRF2S368-P with amino acids 496-506 of mouse MMS19 and 495-505 of human
MMS19.
(F) αTRF2S368-P may cross-react with MMS19 on western blot. Untransfected 293T cells were treated
with 0.02% MMS for four hrs. After transfer of protein to the nitrocellulose membrane, the blot was cut in
half so that it could be individually probed with αMMS-19 (2G2, gift of J. Hoeijmakers) and αTRF2S368P. Before exposure to film, blots were re-aligned, so that co-migration of MMS19 and band on the
αTRF2S368-P blot could be determined.
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The finding that αTRF2S368-P was capable of strongly cross-reacting with
at least one other protein raised the possibility that a similar cross-reactivity might
explain recent data regarding the phosphorylation of another SQ/TQ site within
TRF2, Threonine 188 (T188). A phosphospecific antibody to TRF2
phosphorylated on T188 was used to show that TRF2 is phosphorylated on this
residue in response to IR, and that this form of phosphorylated TRF2 localizes to
dysfunctional telomeres, ALT-associated PML bodies, and unexpectedly, DNA
damage induced by laser micro-irradiation and IR209. The same company that
generated αTRF2S368-P, Anaspec, was used to generate the antibody in this
study, which was designated anti-TRF2 Thr188P.
To determine whether anti-TRF2 Thr188P could cross-react with another
protein present in DNA damage foci, TRF2F/- MEFs infected with a lentiviral vector
were treated with Cre to remove all TRF2 protein (Fig. 3-11A). In MEFs not
exposed to Cre, anti-TRF2 Thr188P staining was weak and occasionally formed
small foci. In cells treated with Cre, TIF formation was monitored by IF for
γH2AX. As was the case for αTRF2S368-P, anti-TRF2 Thr188P signal
colocalized with TIFs after TRF2 depletion (Fig. 3-11B), showing that this
antibody detects a non-TRF2 protein.
To confirm that anti-TRF2 Thr188P was capable of cross-reacting with
another protein present in DNA damage foci, an allele of mouse TRF2 with both
T188 and S366 mutated to alanines was expressed in TRF2F/- MEFs. Since
these are the only two SQ/TQ motifs present in mouse TRF2, the mutant allele is
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completely free of PIKK targets. Cre expression removed endogenous TRF2
(Fig. 3-11A). In cells infected with vector only, Cre expression caused TIF
formation and the anti-TRF2 Thr188P signal strongly colocalized with these DNA
damage foci (Fig. 3-11B). Because these cells no longer contain detectable
TRF2, this indicates that anti-TRF2 Thr188P detects a protein other than TRF2.
Cre was also expressed in cells containing the double phosphorylation mutant of
TRF2 (Fig. 3-11A). This form of TRF2 localized to telomeres as shown by its
colocalization with TRF1 (Fig. 3-11C). TIFs were not observed after Cre
expression in these cells, indicating that the double phosphorylation mutant of
TRF2 prevents telomeres from being recognized as DNA damage (Fig. 3-11D,
No IR). After the introduction of Cre, MEFs were exposed to 5 Gy IR. γH2AX
staining showed the expected IR induced foci, which were also strongly detected
by anti-TRF2 Thr188P (Fig. 3-11D, 5 Gy). The findings that anti-TRF2 Thr188P
detects IR induced DNA damage foci in cells in which the only form of TRF2 no
longer contains a phosphorylatable residue at position 188, and that this antibody
detects TIFs in cells that do not contain TRF2, clearly show that anti-TRF2
Thr188P is capable of cross-reacting with another protein present at sites of DNA
damage.
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Figure 3-11: The anti-TRF2 Thr188P antibody (Tanaka et al., 2005) is not specific for TRF2.
(A) Expression of Cre in TRF2F/- p53-/- MEFs depletes TRF2 protein. TRF2F/- p53-/- MEFs were infected
with an allele of TRF2 with T188 and S368 mutated to alanines (mutant) or a vector control (vector). 120
hrs. after introduction of Cre, cells were harvested and lysates were analyzed by western blot with an antiTRF2 antibody (1254). Non-specific bands detected by the antibody are indicated.
(B) The anti-TRF2 Thr188P (αTRF2T188-P) antibody detects TIFs after TRF2 has been removed.
TRF2F/- p53-/- MEFs infected with vector only were exposed to Cre or left untreated. 120 hrs. after the
introduction of Cre, cells were harvested and IF was performed with a γH2AX antibody and the anti-TRF2
Thr188P antibody. Merged image shows colocalization of the two signals after Cre treatment.
(C) The TRF2 double phospho-mutant allele localizes to telomeres. TRF2F/- p53-/- MEFs were infected
with an allele of TRF2 with T188 and S366 mutated to alanines and exposed to Cre. 120 hrs. after
introduction of Cre, cells were fixed and IF was performed with anti-c-myc to detect the introduced allele
of TRF2 and an anti-TRF1 antibody (644) to detect telomeres.
(D) The anti-TRF2 Thr188P antibody detects IR induced DNA damage foci in cells in which endogenous
TRF2 has been replaced with a mutant allele which contains an unphosphorylatable residue at position 188.
120 hrs. after introduction of Cre, TRF2F/- p53-/- MEFs expressing the mutant allele were subjected to 5 Gy
IR or left untreated. After a one hr. recovery, cells were fixed and IF was performed with a γH2AX
antibody and the anti-TRF2 Thr188P antibody (αTRF2T188-P). Merged image shows colocalization of the
two signals.
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DISCUSSION
We have shown that an antibody designed to detect ATM phosphorylated
on S1981 also detects TRF2 phosphorylated on S368, when TRF2 is expressed
by transient transfection in 293T cells. TRF2 phosphorylation was diminished
when cells were treated with the PIKK inhibitors caffeine and wortmannin, and
augmented by treatment with UV radiation but not IR. Knockdown experiments
show that ATR is a positive regulator of TRF2 phosphorylation on S368, while
reduction of ATM and DNA-PK protein had no effect on TRF2 phosphorylation
levels. Surprisingly, co-transfection of mTOR strongly diminished
phosphorylation of S368 of TRF2.
Because members of the PIKK family, including the ATR orthologs, are
required for telomere length maintenance in yeast, the consequence of mutation
of serine 368 of TRF2 for telomere length maintenance will be explored in the
following chapter. Additionally, the positive regulation of TRF2 phosphorylation
by ATR, but not DNA-PK or ATM, suggests that this modification may be
functionally important during replication of telomeric DNA, an idea that will also
be investigated in the next chapter.
To our knowledge, the finding that co-expression of mTOR had an
inhibitory effect on the phosphorylation of TRF2 on S368 is the first report of a
connection between the mTOR pathway and telomeres. Such a connection
could be utilized in cases when mTOR signaling causes a population of cells to
expand rapidly in response to favorable growth conditions. In many cell types,
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proliferation can be limited by low levels of telomerase activity 224. Perhaps
mTOR, by regulating phosphorylation of shelterin components, can alter the
accessibility of the telomere to telomerase, to prevent telomere length from
limiting cell division. This model has the advantage of providing a rapid way for
mTOR to affect telomere length that does not involve the slower processes of
transcription and translation.
Ironclad evidence of endogenous TRF2 phosphorylated on S368 has been
elusive. However, a recent report confirms that endogenous TRF2 can be
phosphorylated on this residue in vivo in response to IR225. Matsuoka et al.
performed immunoprecipitates using various SQ/TQ specific antibodies on 293T
cells untreated and treated with 10 Gy IR. Mass spectrometry was performed on
the immunoprecipitates to determine the identity of proteins phosphorylated
specifically in response to IR. In immunoprecipitates with both an antibody
specific to ATM S1981 (Rockland) and with αTRF2S368-P described here, a
fragment of TRF2 phosphorylated on S368 and S380 (a second SQ in human
TRF2 which is not conserved in mouse) was recovered. The data presented
indicate only that TRF2 phosphorylation is enriched after IR treatment, it is
unknown whether TRF2 is phosphorylated on S368 in untreated cells.
In our hands, IR treatment did not increase the phosphorylation of TRF2
overexpressed in 293T cells on S368 (Fig. 3-3B) and we did not see an induction
of TRF2 phosphorylation of endogenous TRF2 with low doses of IR (Fig. 3-2A,
vector). Matsuoka et al. were probably able to detect TRF2 phosphorylated on
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S368 in response to IR because immunoprecipitation with phospho-specific
antibodies, followed by mass spectrometric analysis, allowed for higher
sensitivity than western blot on whole cell lysates. Additionally, much greater
levels of IR (10 Gy) were employed, while in the experiments described here,
293T cells were analyzed after IR treatment of only 0.6 Gy. Nonetheless, ATM
activation, as determined by autophosphorylation on S1981, is maximal after 0.4
Gy IR194. It is likely that the high levels of IR employed by Mastsuoka et al.
activated ATR in addition to ATM, because even 5 Gy IR leads to ATR activation,
as determined by Chk1 phosphorylation158.
In spite of difficulties detecting endogenous TRF2 phosphorylated on S368
by western blot, the striking degree of evolutionary conservation of this residue
and the findings of Matsuoka et al. suggest that S368 is a physiologically relevant
phosphorylation site. Endogenous TRF2 phosphorylated on S368 is probably
difficult to detect because it is present at very low levels. 293T transfection
results in TRF2 expression levels several fold higher than endogenous (See Fig.
3-2C) and this may be the simple reason why S368 phosphorylation was only
detected in this setting. Normally TRF2 is present only at the telomere, but when
TRF2 was overexpressed in fibroblasts using a retrovirus, it was observed to
saturate its telomere binding sites and distribute throughout the nucleus115. Since
our data indicate that TRF2 S368 phosphorylation is induced by replication stress
and positively regulated by ATR, it is likely that only a small percentage of TRF2,
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perhaps only TRF2 in the immediate vicinity of a stalled replication fork, will be
phosphorylated on S368.
These studies have highlighted the tendency of antibodies generated
against SQ/TQ phosphorylation events on specific proteins to cross-react with
proteins other than their desired target. By western, the αATM-P antibody
detects TRF2 phosphorylated on S368 as well as at least one other protein
whose phosphorylation is induced by DNA damage. Furthermore, two antibodies
targeting different SQ/TQ motifs in TRF2 (anti-TRF2 Thr188 and αTRF2S368-P)
are capable of detecting a protein other than TRF2 present in DNA damage foci.
The high concentration of SQ/TQ phosphorylated proteins present in DNA
damage foci increases the likelihood of antibody cross-reaction in the IF setting.
In order to use such antibodies for IF, stringent controls must be performed to
rule out the possibility of cross-reaction. The danger of cross-reaction in western
blot applications is mitigated somewhat by the aid of MW information about the
detected protein. Nonetheless, controls are required to confirm the identity of the
detected protein. The study by Matsuoka et al. clearly demonstrates the ability of
SQ/TQ specific antibodies to immunoprecipitate proteins other than their
intended targets. For example, αATM-P immunoprecipitated 15 distinct proteins
which were phosphorylated in response to IR. Interestingly, one study used ChIP
with αATM-P to show that phosphorylated ATM is present at telomeres during
late S and G2 after cell cycle synchronization with thymidine and aphidicolin 226.
However, the authors did not test whether total ATM was detectable at telomeres
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by ChIP during these cell cycle stages, allowing the possibility that the ChIP
signal obtained αATM-P represents TRF2 phosphorylated on S368 rather than
ATM phosphorylated on S1981.
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Chapter 4: Functional Studies of TRF2 S368 Mutation

INTRODUCTION
The studies described in Chapter 3 shed light on the regulation of the
phosphorylation of TRF2 on S368. The checkpoint kinase ATR, which responds
primarily to DNA damage caused by replication stress153 directly or indirectly,
promotes this phosphorylation event. Phosphorylation of TRF2 on S368 is
increased by HU treatment and UV radiation and diminished by siRNA mediated
knockdown of ATR. These findings informed our study of the influence of S368
phosphorylation on TRF2 function.
TRF2 plays a major role in telomere protection and is also implicated in
telomere length regulation. The phenotype of TRF2 loss was first studied using a
dominant negative allele of TRF2 which lacks the N-terminal Basic domain and
the Myb domain, required for DNA binding. Expression of this mutant, TRF2ΔBΔM,
removes TRF2 from telomeres and leads to telomere fusion and growth arrest63.
The double-stranded part of the telomere remains largely intact and is detectable
at the sites of fusion, however the single stranded telomeric overhang is
degraded63. Telomere fusions resulting from TRF2 inhibition are dependent on
DNA Ligase IV and Ku indicating that they are generated by NHEJ105 79 106.
Preceding telomeric fusion, many DNA damage response factors localize to
telomeres including 53BP1, γH2AX, ATM phosphorylated on S1981, Mre11,
Nbs1, and phosphorylated Rad1795 96. Consistent with the induction of a DNA
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damage response, TRF2 loss leads to p53-mediated senescence or apoptosis,
depending on cell type63 102.
The phenotypes of TRF2 inhibition, first observed with the dominant
negative allele, were recapitulated in mouse cells79. Celli and de Lange
generated TRF2F/- MEFs by deleting one allele of TRF2 and flanking the second
TRF2 allele with LoxP sites. By exposing TRF2F/- MEFs to Cre recombinase, the
remaining allele of TRF2 is removed. As was observed with the dominant
negative allele of TRF2, genetic removal of TRF2 results in degradation of the
telomeric 3’ overhang, telomeric fusions, and cell cycle arrest79. Additionally,
Celli and de Lange observed that deletion of TRF2 causes destabilization of
TRF2’s binding partner Rap1. Confirming that the cause of these phenotypes is
the loss of TRF2, each can be repressed by expression of TRF2 from an
exogenous cDNA.
In mouse, the pertinent serine is located at position 366 (Fig. 3-1). By
expressing TRF2 containing a mutation at S366 in TRF2F/- MEFs and removing
endogenous TRF2 by introducing Cre recombinase, the effect of mutation of
S366 on the ability of TRF2 to protect the telomere can be analyzed. Deletion of
TRF2 results in a senescence-like arrest, preventing the procurement of mitotic
samples, so TRF2F/- MEFs that were also deficient for p53 (p53-/-) were used in
these studies. Because the crucial ATM S1981 phosphorylation site closely
resembles the region surrounding TRF2S366, we predicted that S366 could be
involved in preventing the activation of ATM at telomeres.
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In addition to examining its role in telomere protection, we also considered
that phosphorylation of TRF2 on S368 may be involved in regulation of telomere
length by TRF2. In human cells, TRF2 overexpression causes rapid telomere
shortening76 104 and shRNA mediated knockdown of TRF2 leads to telomere
elongation (Takai, K. and de Lange, unpublished). Telomere shortening induced
by TRF2 can occur in the absence of telomerase104,109. It is likely that the
shortening observed upon overexpression of TRF2 is due to a process known as
t-loop homologous recombination (t-loop HR), in which the telomeric t-loop is
thought to serve as a substrate for Holliday Junction resolvases, resulting in
drastic stochastic telomere shortening and the formation of extrachromosomal
telomeric circles21. We investigate whether TRF2 mutated at position 368 can
carry out t-loop HR, by overexpressing these alleles in human cells in which
endogenous TRF2 has been knocked down with shRNA.
A potential role of ATR-mediated phosphorylation of TRF2 on S368
would be of interest given that S. cerevisiae Tel1 and Mec1 (homologs of the
ATM and ATR kinases, respectively) are required for maintenance of telomere
length169 164 227. Similarly, in the fission yeast, S. pombe, absence of Tel1 or Rad3
(the Mec1 homolog), causes telomere shortening171 170. In mammals, some
evidence suggests that ATM and DNA-PK are involved in telomere length
regulation, but this has not been thoroughly investigated179 180 181. Telomere
length changes in the context of ATR deficiency have not been studied, owing
primarily to the essential nature of ATR in mammalian cells228.
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The response of the ATR kinase to DNA replication stress might be
particularly significant in the context of telomeres. In addition to imposing a cell
cycle arrest and preventing late origin firing, a primary function of the ATR kinase
in response to replication stress is to stabilize stalled replication forks229. The
ATR pathway uses at least two parallel strategies to prevent the collapse of
stalled forks and facilitate the restart of DNA replication. First, the ATR kinase
acts to prevent components of the replisome from dissociating from stalled forks.
The S. cerevisiae ATR ortholog, Mec1, and downstream components of the
Mec1 pathway, are required to prevent loss of DNA polymerases from the
replication fork when cells are treated with HU230-232 and chicken DT40 cells that
lack Chk1, the primary mediator of ATR activity, do not retain PCNA at stalled
forks induced by aphidicolin233. Stalled forks can be restarted using
recombination based or non-recombination based mechanisms234(Fig. 4-0).
While most models of replication fork restart involve the formation of a four–way
Holliday Junction “chickenfoot” structure, resolution of these structures by
Holliday Junction endonucleases can result in pathological genome
rearrangements. The ATR pathway appears to have an anti-recombinogenic
effect at stalled forks. Treatment of budding yeast which are deficient for Mec1
with HU results in the formation of foci of the recombination protein Rad52235.
Similarly, HU treatment of fission yeast deficient in the ATR ortholog, Rad3, or
the downstream Cds1 kinase, results in persistent foci of Rad22 (the Rad52
homolog) as well as formation of aberrant structures resembling recombination
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intermediates236. Deletion of the fission yeast Rad51 homolog, Rhp51, reduces
the formation of these structures and increases the proportion of Cds1 mutants
which complete S phase236 consistent with the ATR pathway negatively regulating
deleterious recombination events at stalled forks. The ATR pathway may prevent
recombination at stalled forks by negatively regulating Rad60237 or the Holliday
Junction specific endonuclease component Mus81238,239. There is also evidence
that RecQ helicases promote non-recombinogenic fork-restart pathways at
stalled forks240,241 possibly by facilitating the reverse branch migration of
regressed (chickenfoot) forks, by-passing the fork-stalling lesion and avoiding
resolution by a Holliday Junction-specific nuclease242.
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Fig. 4-0: Stalled replication forks can be restarted by recombination-dependent and nonrecombination dependent mechanisms.
Replication forks stall when encountering certain types of lesions, here shown as a ♦ on the lagging strand
template. When forks encounter such a lesion, the newly formed strands regress to form a four-way
Holliday junction “chickenfoot” structure. In non-recombination based models of fork restart, the nascent
lagging strand is extended using the nascent leading strand as a template. This allows the lesion to be
bypassed or allows time for it to be removed. When the regressed fork is reversed, replication can restart
directly. In recombination-based models of fork restart the “chicken-foot” is resolved by Holliday junction
specific nucleases. After the lesion is removed, a strand invasion event takes place between the broken
chromosome and the intact duplex. Replication restart can take place, but genome rearrangement may have
occurred. This figure was adapted from Heller and Marians, 2007234.
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Single-stranded DNA is thought to be the major structure which signals
replication stress and activates the ATR pathway243. Single-stranded DNA is
coated with RPA, which binds and recruits the ATR/ATRIP complex119 a
replication fork stalls, single-stranded DNA may be generated in several different
ways. Depending on where the fork-blocking lesion is located, dissociation of the
replisome could leave either the single-stranded leading or lagging strand
template uncovered. Another possibility is that the replicative helicases become
“uncoupled” from the polymerases and continue unwinding duplex DNA even
though the fork has stalled. This has been observed when forks are stalled by
treatment with aphidicolin which inhibits DNA polymerases244 UV and cisplatinum245.
Replication forks may also stall without creating large amounts of ssDNA.
This is the case when the replication fork encounters the protein-DNA complexes
which form the rRNA Replication Fork Barriers (RFBs) of S. cerevisiae246. When
a similar RFB was inserted ectopically into the S. pombe genome, Rad3 status
did not affect viability, indicating that fork stabilization mediated by the ATR
pathway is not required when replication forks encounter this type of barrier247.
In theory, telomeric DNA presents several obstacles to the efficient
passage of the replication fork. The G-rich strand of telomeric DNA can form
quadruplex structures under certain conditions186 which could prevent the
passage of the replication fork187. Repeats can also lead to the formation of other
unusual structures, such as H-DNA and “sticky” DNA, and may cause
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polymerase slippage188. Furthermore, telomere-specific DNA binding proteins
might hinder the passage of the replication fork, as is the case with the wellstudied E. coli Tus protein189.
Several lines of evidence indicate that the passage of the DNA replication
fork through telomeric DNA is hindered. Telomeric DNA is a poor substrate in
the in vitro replication system of linear SV40 DNA190 and EM analysis of synthetic
model replication forks consisting of telomeric DNA show frequent fork
regression, often resulting in four-stranded chickenfoot structures191. In vivo,
replication forks proceed slowly through telomeric DNA in S. cerevisiae192 193.
High levels of TRF1 and TRF2 cause replication forks to stall at telomeric DNA
both in vitro190. Interestingly, studies in Xenopus egg extracts showed that TRF1
dissociates from telomeric chromatin in a cell cycle dependent manner, possibly
corresponding to the time when telomeres are replicated248.
Replication fork progression through telomeric DNA could be facilitated by
the recruitment of shelterin-associated factors. For example, TRF2 physically
interacts with the RecQ helicases WRN and BLM and can stimulate their helicase
activity on substrates resembling telomeric DNA137 138. RecQ helicases are
believed to facilitate replication fork progression by disrupting obstructing DNA
structures, including G quadruplex DNA, and may also play a role in the
reinitiation of replication after fork collapse139. Impaired WRN function has
deleterious consequences for telomeres that may be related to problems during
telomere replication. Overexpression of a dominant negative WRN allele results
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in the loss of lagging strand telomeres52 249. Late passage MEFs which are
doubly deficient for WRN and telomerase exhibit frequent sister telomere
exchanges, one possible outcome of replication fork collapse within a
telomere140. Additionally, primary fibroblasts which lack WRN function undergo
senescence which can be reversed by expression of telomerase49. A potential
role for TRF2 in the replication of telomeric DNA is also suggested by the recent
finding that in the absence of the S. pombe TRF1/TRF2 ortholog Taz1,
replication forks stall as they approach telomeric DNA250.
TRF2 S368 is conserved immediately adjacent to the TIN2 binding site in
both human and mouse TRF2 (Fig. 3-1). This is especially notable because the
hinge domain is the region of TRF2 least conserved between human and mouse,
with only 70% amino acid identity60. This positioning raises the possibility that
phosphorylation of TRF2 on S368 could influence the interaction between TRF2
and TIN2. A mechanism to modulate the interaction between TRF2 and TIN2
could be significant because the stable presence at the telomere of all shelterin
components is influenced by TIN2. TIN2 can bind TRF1 and TRF2
simultaneously, and disruption of this interaction results in decreased telomeric
TRF1 and TRF2, and a DNA damage response at telomeres64 65. TIN2 also
binds TPP1 and is required for its localization to the telomere, and TPP1, in turn
recruits POT1, and in mice, Pot1a and Pot1b66 67 68.
This chapter describes experiments designed to test the role of
phosphorylation on S368 in the function of TRF2. The effect of mutation at S368
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on the protective function of TRF2 is examined. Additionally, telomere length
homeostasis and the telomeric response to replication stress in cells expressing
TRF2 phosphorylation mutants are analyzed. In search of a potential mechanism
to explain the observed phenotypes of expression of the TRF2 phosphorylation
mutants, the influence of phosphorylation status on the interaction between TRF2
and its binding partners is explored.

RESULTS

Isolation of MEF cell lines expressing TRF2 S366 mutants
Two different mouse TRF2 phosphorylation mutants were introduced into
conditional TRF2F/- p53-/- MEFs. S366 was replaced with either an alanine
(S366A) to mimic the unphosphorylated residue or a glutamate (S366E) to mimic
constituitive phosphorylation. Wildtype TRF2 (wtTRF2) or the empty lentiviral
vector were introduced into the same cells as controls.
Western blotting showed that the introduced alleles were expressed at
higher levels than endogenous TRF2 (Fig. 4-1A). Since such supra-physiologic
expression levels might compensate for subtle defects of the mutants, clonal
populations with lower levels of TRF2 were isolated. Such clones also
circumvent a second problem, cell to cell variation in expression level of the
introduced allele (Fig. 4-1B). Clones were chosen for further use if their TRF2
expression was homogenous and comparable to endogenous TRF2 (Fig. 4-2).

86

Figure 4-1: Introduction of TRF2 S366 mutant alleles into TRF2F/- p53-/- MEFs.
(A) TRF2F/- p53-/- MEFs were infected with either myc tagged wildtype TRF2 (wtTRF2), TRF2 with S366
mutated to alanine (S>A), TRF2 with S366 mutated to glutamate (S>E), or the empty lentiviral vector.
MEFs were not treated with Cre. Cell lysates from infected MEFs were analyzed by western blot with
antibody 1254 against mouse TRF2. Non-specific bands detected by the antibody are indicated.
(B) Infected MEFs, not treated with Cre, were analyzed by IF with anti-c-myc and an antibody against
mouse TRF1 (644).
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Figure 4-2: TRF2F/- p53-/- clonal cell lines expressing TRF2 S366 mutant alleles.
(A) Clonal cell lines were derived from TRF2F/- p53-/- MEFs infected with myc-tagged TRF2 alleles. 120
hrs. after Cre exposure, cells were harvested. Cell lysates were analyzed by western blot with antibody
1254 against mouse TRF2. Non-specific bands detected by the antibody are indicated.
(B). IF was performed with anti-c-myc and an antibody against mouse TRF1 (644).
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TRF2 S366 mutants localize to telomeres, stabilize Rap1, and prevent telomeres
from activating the DNA damage response
To determine whether the TRF2 S366A and TRF2 S366E mutants are
positioned at telomeres, their cellular localization was analyzed by IF 120 hrs.
after Cre was introduced to remove endogenous TRF2. The efficiency of Cremediated deletion of TRF2 was determined by loss of endogenous TRF2
expression in the vector expressing cells. Both mutants colocalized extensively
with the telomeric protein TRF1, indicating that they localize to telomeres (Fig. 42B). Telomeric localization of TRF2 S366A and TRF2 S366E was confirmed by
ChIP (Fig. 4-3A,B). Additionally, ChIP showed that the telomeric localization of
the other shelterin components were not perturbed in the presence of TRF2
S366A and TRF2 S366E (Fig. 4-3A,B).
Differential salt extraction on MEFs expressing TRF2 S366A and TRF2
S366E was performed to determine if mutation at S366 affects the chromatin
association of TRF2. Cells were lysed in buffer containing 150 mM KCl and
subsequently extracted with buffer containing 420 mM KCl to release chromatinbound proteins. As expected, γ-tubulin localized primarily to the 150 mM soluble
fraction while the majority of wildtype TRF2 was present in the chromatin bound
420 mM fraction, as has been reported previously 251. Mutation at S366 did not
significantly affect the distribution of TRF2 between the soluble and chromatinbound fractions (Fig. 4-3C).
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Figure 4-3: TRF2 S366 mutation does not affect shelterin localization.
(A) ChIP was performed on the indicated cell lines 120 hrs. after introduction of Cre. Immunoprecipitated
DNA was blotted onto a membrane and probed with the telomere specific γ32-P end-labeled oligonucleotide
probe (CCCTAA)4. Antibodies used were TRF2: 1254, TRF1: 644, Rap1: 1252. TIN2: 1447, TPP1: 1151,
POT1A: 1220, POT1B: 1223, myc: anti-c-myc, 9E10 (Calbiochem). PI stands for Pre-Immune serum
(from animal used to generate Rap1 antibody 1252).
(B) Quantitation of signals in (A).
(C) TRF2 S366 mutation does not affect the chromatin association of TRF2. 120 hrs. after the introduction
of Cre, uncloned cell populations expressing the indicated alleles of TRF2 were lysed in buffer containing
150 mM KCl. Chromatin bound proteins were subsequently extracted using 420 mM KCl. The remaining
pellet was lysed in Laemmli buffer and sonicated. Lysates were analyzed by western blot with anti-c-myc
and anti-γtubulin.
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In order to assess the function of TRF2 S366A and TRF2 S366E, the
ability of these alleles to stabilize Rap1 was examined after introduction of Cre to
remove endogenous TRF2. Western blotting and IF analysis showed that both
mutant alleles stabilized Rap1 as efficiently as wildtype TRF2 (Fig. 4-4).
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Figure 4-4: TRF2 S366 mutants stabilize Rap1.
(A) MEFs infected with wildtype TRF2, TRF2 S366 mutants, or an empty lentiviral vector were exposed to
Cre. 120 hrs. after Cre introduction, cells were harvested and western blot was performed with antibodies
against mouse TRF2 (1254) and mouse Rap1 (1252). MEFs infected with vector but not exposed to Cre
are included for comparison.
(B) IF was performed on indicated cell lines harvested 120 hrs. after Cre exposure, with anti-c-myc and an
antibody against mouse Rap1 (1252).
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TRF2 S366A and TRF2 S366E prevented telomeres from activating the
DNA damage response. Whereas vector-infected cells showed the expected
induction of 53BP1 TIFs after exposure to Cre, TIFs did not form in the clones
containing TRF2 S366A or TRF2 S366E, as was the case for cells expressing
wildtype TRF2 (Fig. 4-5). Cre-treated cells of each of the clonal lines often
exhibited several (usually 1-4) 53BP1 foci, but in less 2% of cells did more than
two of these foci colocalize with telomeric DNA. Consistent with their lack of a
DNA damage response, cells containing mutant versions of TRF2 did not arrest,
but grew at a similar rate to cells infected with wildtype TRF2 (Fig. 4-6). There
was no evidence for positive selection of cells which had not been exposed to
Cre, as expression of mutant alleles was maintained at the same level over time.
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Figure 4-5: TRF2 S366 mutants prevent TIF formation.
120 hrs. after the introduction of Cre, the indicated cells lines were fixed. IF was performed for 53BP1
(Novus) in conjunction with FISH with a PNA probe specific for telomeric repeats. Colocalization of
53BP1 with telomeres in vector cells indicates the presence of TIFs.
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Figure 4-6: MEFs expressing TRF2 S366 mutants grow at a normal rate.
Growth curve of uncloned populations of cells expressing wildtype TRF2 or S366 mutant alleles. Growth
curve begins 120 hrs. after the introduction of Cre.

In addition to being proficient in repressing a DNA damage response at
telomeres, the TRF2 S366A and S366E alleles prevented unscheduled DNA
repair at chromosome ends. Whereas single-stranded telomeric DNA was
degraded in vector control cells lacking TRF2, cells containing wildtype TRF2 or
the phosphorylation mutants showed no reproducible decrease in the amount of
single-stranded DNA signal (Fig. 4-7). Furthermore, telomere fusions were not
observed in cells expressing either wildtype TRF2 or either of the
phosphorylation mutants. Telomere fusions were readily detected in the vector
controls cells by telomeric DNA in-gel hybridization (Fig. 4-7) and on metaphase
spreads (Fig. 4-8).
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Figure 4-7: TRF2 S366 mutants prevent telomeric overhang loss and fusions.
(A) 120 hrs. after the introduction of Cre, cells were harvested from the indicated clonal cell lines. DNA
was digested with MboI restriction endonuclease and subjected to PFGE. In-gel hybridization was
performed under native conditions and the telomeric overhang was detected by probing with the γ-32P end
labeled oligonucleotide probe (CCCTAA)4 (Left). DNA was denatured in situ and reprobed (Right).
(B) 120 hrs. after the introduction of Cre, cells were harvested from the indicated uncloned cell populations
and treated as in (A).
(C) Overhang signal was quantitated using ImageQuant software and normalized to the total telomeric
signal obtained after denaturation. For each experiment, the normalized value for overhang signal was set
to one for cells expressing wildtype TRF2 and relative values for other samples are shown.
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Figure 4-8: TRF2 S366 mutants prevent telomere fusions.
Metaphase spreads of the indicated cell lines were obtained 120 hrs. after the introduction of Cre. FISH
was performed with a telomere-specific probe (green) and DNA was counterstained with DAPI (red).
Chromosomal fusions containing telomeric DNA at the site of fusion were counted for the indicated cell
lines.

The effect of TRF2 S366 mutation on Sister Telomere Exchange
To determine whether phosphorylation of TRF2 on S366 plays a role in
the repression of homologous recombination at telomeres, MEFs expressing
TRF2 S366A and TRF2 S366E were subjected to chromosome-orientation
fluorescent in situ hybridization (CO-FISH). CO-FISH, by differentially labeling
the parental TTAGGG and CCCTAA strands of sister telomeres in metaphase
spreads, allows the detection of telomere sister-chromatid exchanges (T-SCE).

98

The frequency of sister telomere exchange was found to be between 0.02 and
0.04 exchanges per chromosome end, consistent with what has previously been
reported106. However, no significant difference was found between the Cretreated clonal lines expressing wildtype TRF2 and those expressing the
phosphorylation mutants (Fig. 4-9).
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Figure 4-9: S366 mutation does not affect frequency of Telomere Sister Chromatid Exchange.
(A) 120 hrs. after the introduction of Cre, the indicated cell lines were incubated for 14 hrs. in the presence
of BrdU and BrdC and metaphase spreads were prepared. Spreads were subjected to CO-FISH with a Grich telomere specific probe (green) and a C-rich specific probe (red), and stained with DAPI (blue).
(B) Quantification of frequency of Telomere Sister Chromatid Exchange

100

The effect of TRF2 S366 mutation on telomere length control in mouse cells
To study telomere length homeostasis in the presence of TRF2 S366
mutants, we returned to the uncloned cell populations for each allele of TRF2,
thereby avoiding the complications of clonal variations in telomere length. The
uncloned cell populations were treated with Cre, and their telomere length was
monitored over time. No significant change in telomere length was observed
over the first 150 PDs (Fig. 4-10A). Eventually, MEFS expressing TRF2 S366E
began to exhibit dramatic telomere lengthening, while in wildtype TRF2
expressing cells, telomere length remained relatively constant (Fig. 4-10A). The
telomere lengthening in the presence of TRF2 S366E was apparent both in
bands representing individual longer telomeres (indicated by * in Fig 4-10A) and
in the bulk population of telomeres between approximately 25 and 50 kb. In the
presence of TRF2 S366A, subtle changes in telomere length were observed.
Individual longer telomeres (represented by discrete bands of higher MW) slightly
decreased in length, while the bulk telomere length population appeared to
slightly elongate and become less heterogeneous. Western blotting showed that
expression of the introduced alleles was maintained throughout the experiment
(Fig. 4-10B). The experiment was repeated and the changes in telomere length
observed in the initial experiment were not reproduced (Fig. 4-10C).
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Figure 4-10: Telomere length changes in uncloned populations of cells expressing wildtype TRF2 or
S366 phosphorylation mutants.
(A) Uncloned populations of cells expressing wildtype TRF2 or phosphorylation mutants were exposed to
Cre (see Fig 4-6 for growth curve) and DNA samples were taken periodically. DNA was subjected to
PFGE and telomeres were detected by in-gel hybridization under denaturing conditions with a telomeric
probe. Asterisks indicate bands representing individiual high MW telomeres.
(B) Expression of TRF2 alleles is maintained throughout the experiment. Cells were harvested at the
termination of the experiment and lysates were analyzed by western blotting with an antibody against
mouse TRF2 (1254). Cells infected with vector and not exposed to Cre are included to show levels of
endogenous TRF2.
(C) Uncloned populations of cells were again exposed to Cre and telomere length was followed as in (A).
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The effect of TRF2 S368 mutation on telomere length control in human cells
The effect of TRF2 S368 mutation on telomere length was also analyzed
in human cells, which are a more established system for the study of telomere
length regulation than mouse cells. For this purpose, a HeLa subclone (Hela
204) was used with short and stable telomeres, so that telomere length changes
could be easily monitored. An shRNA targeting the 5’ UTR of TRF2 was used to
stably knockdown TRF2 levels to nearly undetectable levels (Fig. 4-11A), and
cells were subsequently infected with either wildtype TRF2, TRF2 S368A, TRF2
S368E, or the empty vector. However, after the experiment was finished it was
discovered that the construct used to express TRF2 S368E contained a cloning
abnormality resulting in the duplication of amino acids 362-374. Cells grew
similarly (Fig. 4-11B) and telomere length changes were measured over
approximately 80 PDs. As previously observed (Takai and de Lange,
unpublished), reduced levels of TRF2 lead to telomere lengthening (Fig. 4-11C).
Also as expected, overexpression of wildtype TRF2 shortened telomeres,
potentially due to t-loop HR. Interestingly S368A expressing cells and cells
expressing the abnormal TRF2 S368E construct did not shorten, suggesting that
these mutants are incapable of facilitating t-loop HR. This experiment must be
repeated to confirm these findings and also to ensure that all alleles of TRF2 are
still expressed at the end of the experiment.
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Figure 4-11: Telomere length changes in human cells overexpressing wildtype TRF2 and TRF2 S368
mutants.
(A) HeLa clonal cell line 204 was treated with an shRNA targeting the 5’ UTR of TRF2 (sh#5) or an
shRNA targeting luciferase (luc sh). Subsequently, cells were infected with wildtype TRF2,
phosphorylation mutant alleles, or the pWZL retroviral vector. After 10 days hygromycin selection, cells
were harvested and western blot was performed with an anti-TRF2 antibody (Upstate).
(B) Growth curve of Hela 204 cells infected with TRF2 alleles or vector. Growth curve starts 10 days after
beginning hygromycin selection.
(C) After hygromycin selection, cells were grown for over 70 PDs and samples were taken periodically.
DNA was digested with MboI and AluI and separated on a 0.7% gel. Southern Blot was performed using a
telomere-specific probe.
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The effect of TRF2 S366 mutation on the telomeric response to replication stress
To determine whether the presence of TRF2 mutated at S366 affected
cellular survival under conditions of DNA replication stress, cells expressing
wildtype TRF2, TRF2 S366A, or TRF2 S366E, and wildtype MEFs immortalized
with SV40 Large T antigen (“Control MEFs”) were exposed for 24 hrs. to a low
dose (0.3 µM) of the DNA polymerase inhibitor aphidicolin. After the drug was
removed, cells were grown in fresh media and survival was determined by colony
formation 3-4 days later. Both clonal cell lines expressing TRF2 S366E were
much less sensitive to aphidicolin than the control MEFs or the clonal cell lines
expressing wildtype TRF2 or TRF2 S366A (Fig. 4-12).
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Figure 4-12: Expression of TRF2 with a phosphomimetic mutation at position 366 enhances survival
after aphidicolin.
MEFs expressing the indicated TRF2 alleles were infected with the pWZL-Cre retrovirus and selected with
hygromycin for seven days. Control cells are MEFs wildtype at the TRF2 locus immortalized with the
SV40 Large T antigen. Cells were either untreated or exposed to 0.5 µM or 1 µM aphidicolin. For each
experiment, 500 cells per well were plated in triplicate in 6 well dishes, for each dose. After 24 hrs., media
containing aphidicolin was removed and cells were grown in fresh media until colony formation was
apparent, about 3-4 days. Cells were fixed, stained with Coomassie, and colonies were counted. The
average of three wells for each dose was taken. For each experiment, the mean number of surviving
colonies at each aphidicolin dose was normalized to mean number of colonies present in the untreated
wells. For each cell type, the mean of three independent experiments is shown. Error bars represent
standard deviation.

Metaphase spreads were obtained from the control MEFs and the cell
lines expressing wildtype TRF2 or the phosphorylation mutants, which had been
untreated or treated with 0.3 µM aphidicolin for 24 hrs. As a measure of global
genome damage as a result of aphidicolin treatment, chromatid breaks were
quantified. Consistent with the survival data, both clonal cell lines expressing
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TRF2 S366E exhibited a much smaller induction of chromatid breaks after
treatment with aphidicolin, than the control MEFS or the clonal cell lines
expressing wildtype TRF2 or TRF2 S366A (Fig. 4-13).

Figure 4-13: TRF2 S366 mutants affect the magnitude of chromatid breakage induced by
aphidicolin.
(A) MEFs expressing the indicated TRF2 alleles were infected with the pWZL-Cre retrovirus and selected
with hygromycin for seven days. Control cells are MEFs wildtype at the TRF2 locus immortalized with the
SV40 Large T antigen. Cells were either untreated or treated with 0.3 µM aphidicolin for 24 hrs.
Metaphase spreads were obtained and stained with DAPI (red). White arrows indicate chromatid breaks.
(B) Over 1000 chromosomes of each cell type were analyzed for the presence of chromatid breaks in two
independent experiments. Error bars represent standard deviation.
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Induction of 53BP1 foci was observed in control MEFs and in MEFs
expressing TRF2 S366 mutants and co-staining with a telomeric probe revealed
that many of the induced foci colocalized with telomeres (Fig. 4-14).
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Figure 4-14: Many 53BP1 foci induced by aphidicolin treatment localize to telomeres.
MEFs expressing the indicated TRF2 alleles were infected with the pWZL-Cre retrovirus and selected with
hygromycin for seven days. Control cells are MEFs wildtype at the TRF2 locus immortalized with the
SV40 Large T antigen. Cells were either untreated or treated with 0.3 µM aphidicolin for 24 hrs. IF was
performed with an antibody for 53BP1 (Novus) in conjunction with FISH with a PNA probe specific for
telomeric repeats.
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However while aphidicolin treatment resulted in approximately 33 53BP1
foci per cell in control MEFs, the same treatment resulted in an average of only 7
53BP1 foci per cell in MEFs expressing S366E (Fig. 4-15A). In control MEFs and
MEFs expressing wildtype TRF2 and S366A, a startling percentage, 25-28%, of
the induced foci colocalized with telomeres (Fig. 4-15B). A similar result has been
observed in human cells (van Overbeek and de Lange, unpublished). Similarly,
in MEFs expressing TRF2 S366E, a large fraction of the induced foci colocalized
with telomeres, however there was a small but significant reduction in the fraction
of 53BP1 foci that localized to telomeres (p < 0.05, Student’s T test comparing
wtTRF2-4 and S>E-2) (Fig. 4-15B).
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Figure 4-15: MEFs expressing TRF2 containing a phosphomimetic mutation at S366 exhibit fewer
53BP1 foci after aphidicolin treatment, and a smaller percentage of the induced 53BP1 foci colocalize
with telomeres.
(A) MEFs expressing the indicated TRF2 alleles were infected with the pWZL-Cre retrovirus and selected
with hygromycin for seven days. Control cells are MEFs wildtype at the TRF2 locus immortalized with the
SV40 Large T antigen. Cells were either untreated or treated with 0.3 µM aphidicolin for 24 hrs. IF was
performed with an antibody for 53BP1 (Novus) in conjunction with FISH with a PNA probe specific for
telomeric repeats. For each cell type, over 60 random cells were imaged in two independent experiments.
Errors bars indicate standard deviation.
(B) Quantification of 53BP1 foci induced by aphidicolin treatment in (A) which colocalize with telomeric
signal. Error bars represent standard deviation.
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TRF2 S368 phosphorylation affects the efficiency of the TRF2-TIN2 interaction
In order to determine whether TRF2 S368 phosphorylation status affected
the interaction between TIN2 and TRF2, Flag-tagged TIN2 and several myc
tagged TRF2 mutants were co-transfected into 293T cells. TRF2ΔT, a TRF2
mutant from which the residues required for in vitro TIN2 interaction have been
deleted, was included as a negative control. Immunoprecipitation was performed
with antibodies against TRF2 and TIN2, and their interaction was analyzed by
western blotting with Flag and Myc antibodies. As predicted, TRF2ΔT no longer
interacted with TIN2 (Fig. 4-16A). Reproducibly, immunoprecipitations of TRF2
with a phosphomimetic mutation at S368 (aspartate) contained significantly less
TIN2. Conversely, immunoprecipitations of TRF2 containing a glycine at S368 to
mimic the constituitively unphosphorylated residue, contained slightly more TIN2.
When TIN2 was immunoprecipitated, the same pattern was present but was less
pronounced. An important caveat to this experiment is the presence of
endogenous wildtype TRF2 in the cell lysates, which is not distinguished from the
transfected TRF2 by the antibodies used for immunoprecipitation. Presence of
endogenous TRF2 may cause these experiments to underestimate the
magnitude of the impact of S368 mutation on the interaction between TIN2 and
TRF2.
Because a phosphomimetic mutation at S368 resulted in reduced
interaction with TIN2, we sought to determine whether the increased resistance
to aphidicolin observed in cells expressing TRF2 S366E was due to decreased
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association of TRF2 with TIN2. To this end, we tested the aphidicolin sensitivity
of two clonal cell lines expressing mouse TRF2ΔT, a mutant missing the amino
acids required for the interaction between TRF2 and TIN2. TRF2ΔT expressing
cells did not exhibit increased resistance to aphidicolin (Fig. 4-16B).
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Figure 4-16: A phosphomimetic mutation at position S368 weakens the interaction between TRF2
and TIN2, but expression of a TRF2 mutant lacking the TIN2 interaction domain does not enhance
survival in aphidicolin.
(A) Myc-tagged wildtype TRF2 (WT), TRF2 with S368 mutated to a glycine (S>G), TRF2 with S368
mutated to an aspartate (S>D), or TRF2 lacking the TIN2 interaction domain (ΔT) and alleles of TRF2
flag-tagged TIN2 were co-transfected into 293T cells. 48 hrs. after transfection, cells were harvested and
TRF2 was immunoprecipitated using antibody 647 and TIN2 was immunoprecipitated using antibody 864.
Immunoprecipitates were analyzed by western blot with anti-c-myc and anti-Flag.
(B) MEFs expressing the indicated TRF2 alleles were infected with the pWZL-Cre retrovirus and selected
with hygromycin for 7 days. Control cells are MEFs wildtype at the TRF2 locus immortalized with the
SV40 Large T antigen. Cells were either untreated or exposed to 0.5µM or 1µM aphidicolin. For each
dose, 500 cells per well were plated in triplicate in 6 well dishes. After 24 hrs., media containing
aphidicolin was removed and cells were grown in fresh media until colony formation was apparent, about
3-4 days. Cells were fixed and stained with Coomassie and colonies were counted. Mean number of
surviving colonies at each aphidicolin dose was normalized to mean number of colonies present in the
untreated wells.
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DISCUSSION
TRF2 containing mutations at the putative ATR phosphorylation site,
S366, localized to telomeres and prevented telomeres from being recognized by
the DNA damage response. Expression of TRF2 S366A and TRF2 S366E
prevented TIF formation, overhang degradation, and telomere fusion. TRF2
S366A and TRF2 S366E expressing cells exhibited normal levels of T-SCE.
Mutation at position 368 seems to be able to affect telomere length
regulation in some settings. Dramatic telomere lengthening occurred in MEFs
expressing TRF2 S366E during the course of the first long-term telomere length
study. However, when the experiment was repeated, the telomere length change
was not reproduced. Because culture conditions such as serum composition can
affect telomere length (Ye and de Lange, unpublished), it is possible that an
unidentified idiosyncrasy in culture condition led to the observed lengthening in
one experiment and not the other.
In human cells, initial experiments suggest that overexpression of TRF2
S368 mutants does not result in telomere shortening, as is observed when
wildtype TRF2 is overexpressed. Because telomere shortening caused by
overexpression of TRF2 is thought to result from t-loop HR21, S368 mutants may
be unable to influence this process.
We have shown that telomeres suffer a disproportionately large
percentage of the damage caused when replication forks are stalled with
aphidicolin. In wildtype cells, 25% of aphidicolin induced 53BP1 foci colocalized
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with telomeres. Surprisingly we found that expression of TRF2 containing a
phosphomimetic mutation at position 366 (TRF2 S366E) improved cellular
survival after aphidicolin treatment. Expression of TRF2 S366E decreased the
total amount of chromatid breaks and 53BP1 foci induced by aphidicolin.
In spite of having a genome-wide effect, several lines of evidence indicate
that TRF2S366E is acting through a telomere based mechanism to improve the
outcome to aphidicolin. Improved outcome was shown in two separate clonal cell
lines where S366E is present at similar levels as endogenous TRF2 (Fig. 4-2A)
and localizes primarily to telomeres (Fig. 4-2B). Even though S366E is not
present at high levels and it localizes primarily to telomeres, it is still formally
possible that its observed effects are due to its ability to titrate an unknown factor
away from the rest of the genome. However, it is difficult to propose a factor
whose titration away from stalled forks would improve their resolution. In fact,
known TRF2 interacting proteins, WRN and BLM, if prevented from localizing to
stalled replication forks by TRF2S366E, would be predicted to make the situation
worse, not better.
Additionally, in the presence of TRF2 S366E, a small but significant
decrease in the percentage of aphidicolin induced 53BP1 foci localized to
telomeres. We believe that it is likely that by relieving replication stress
specifically at the telomere, S366E improves the outcome of aphidicolin
treatment for the whole genome. We propose that the high percentage of stalled
forks observed at telomeres after aphidicolin act as a sink for replication fork
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processivity factors. This telomeric sink would enhance the effect of aphidicolin
on the rest of the genome, increasing the frequency of fork stalling, and also
increasing the likelihood that stalled forks will not be reinitiated and form DSBs.
It is possible that TRF2 might facilitate the passage of the replication fork
through telomeric DNA by recruiting and/or regulating the RecQ helicases BLM
and WRN. TRF2 has been shown to interact with both of these helicases and to
be able to stimulate their helicase activity on telomeric DNA substrates. Perhaps
S366 phosphorylation regulates TRF2’s interaction with these proteins. RecQ
helicases may facilitate passage of the replication fork through telomeric DNA by
unwinding G-quartet structures. Additionally, RecQ helicases can facilitate restart of stalled forks by promoting the formation and branch migration of stalled
forks (chickenfeet)139.
Another non-mutually exclusive model for TRF2 S368 phosphorylation to
be able to relieve replication stress at the telomere is through its effect on the
TRF2-TIN2 interaction: a phosphomimetic mutation at S368 slightly diminished
the ability of TRF2 to interact with TIN2. Replication stress at the telomere would
locally activate ATR resulting in the phosphorylation of TRF2 on S368.
Phosphorylation on S368 is expected to weaken the interaction between TRF2
and TIN2, which could change the stability of the entire shelterin complex,
perhaps “loosening” its association with chromatin so that the replication fork can
more easily pass. However, expression of an allele of TRF2 which no longer
interacts with TIN2 (TRF2ΔT) did not lead to the increased resistance to
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aphidicolin seen when TRF2 S366E is expressed, indicating that the increased
resistance cannot be simply explained by loss of the TRF2/TIN2 interaction. It is
likely that the effect of phosphorylation of S366 relieves replication stress at the
telomere through a more subtle and complex mechanism. One possibility is that
TRF2 S366 acts as a molecular switch at times of replication stress at the
telomere, weakening TRF2’s interaction with TIN2, while strengthening TRF2’s
interaction with WRN or additional protein(s) which facilitate replication fork
processivity.

119

Chapter 5: Discussion

TRF2 CAN INHIBIT ATM ACTIVATION
TRF2 prevents telomeres from activating a DNA damage response that is
dependent on the checkpoint kinase ATM. Here we explored one potential
mechanism by which TRF2 performs this function. We showed that TRF2 can
prevent ATM autophosphorylation on S1981 in response to IR, an event which is
critical for the signaling function of ATM, at least in humans. Taken together with
the finding that ATM and TRF2 directly interact, this suggests that TRF2 itself can
inhibit the activation of ATM.
The mechanism by which TRF2 directly inhibits ATM is currently unknown.
In the ATM activation model proposed by Bakkenist and Kastan, an as yet
undetermined signal from damaged chromatin causes multimeric ATM to
autophosphorylate and dissociate into its active, monomeric form. Bakkenist and
Kastan showed that 0.5 Gy IR, which causes approximately 18 DSBs per
nucleus, results in the phosphorylation of over 50% of ATM on S1981. To
explain this, they propose that DSBs cause a topological change in chromatin
which can be detected throughout the nucleus. Alternatively, activation and
dissociation of ATM molecules in the immediate vicinity of DNA damage could
magnify the signal by phosphorylating additional molecules of ATM, leading to a
chain reaction of ATM activation that would ultimately result in a large portion of
the nucleoplasmic pool of ATM being phosphorylated. Like ATM, TRF2 exists as
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a dimer or higher order multimer, raising the possibility that TRF2 interaction with
ATM could act as a clamp to prevent ATM that is activated at the telomere from
dissociating and amplifying the DNA damage signal. We attempted to test this
model, but were unable to detect multimeric ATM in unperturbed cells.
Another possibility is raised by the finding that a region within the flexible
hinge domain of TRF2 strongly resembles the region surrounding S1981 of ATM.
When ATM is in its inactive multimeric state, the kinase domain of one ATM
molecule interacts with the autophosphorylation site of another molecule.
Perhaps the TRF2 hinge domain blocks the phosphorylation of ATM at the
telomere by acting as a decoy for the ATM S1981 phosphorylation site. Several
lines of evidence argue against this model. TRF2 was shown to interact with
amino acids 1439-2138 of ATM, which do not contain its kinase domain.
Furthermore, this model predicts that activated ATM would phosphorylate TRF2
on the site which resembles the ATM autophosphorylation site, and it does not
appear to do so.
Activation of ATM at telomeres when TRF2 is removed may not only be
due to loss of the direct inhibition of TRF2 by ATM. The concomitant removal of
the shelterin binding partners of TRF2, Rap1, and TIN2, may also be responsible.
So far, siRNA mediated knockdown of Rap1 has not yielded conclusive
information regarding the protective function of this protein, and definitive
identification of the contribution of Rap1 to telomeric protection awaits the
generation of a genetic knockout. However, expression of a TRF2 mutant,
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TRF2ΔT, which does not interact with TIN2, results in TIF formation (Donigian et
al., in prep.). If the DNA damage response observed when TRF2 is removed
from telomeres is due to loss of TIN2, TIF formation induced by TRF2ΔT
expression should be dependent on ATM. Another possibility is that TRF2ΔT
causes a DNA damage response at telomeres because recruitment of TPP1 and
Pot1 is diminished in this setting. In this case, the DNA damage response
induced by TRF2ΔT should be dependent on the ATR kinase. Experiments are
currently underway to distinguish between these two possibilities.
TRF2 may also prevent ATM activation at the telomere by modifying the
chromosome terminus so that it does not resemble a DSB, perhaps by promoting
the formation of t-loops. Because TRF2 removal causes degradation of the 3’
overhang, it is predicted to disrupt t-loops, making it difficult to discern whether
loss of t-loops upon TRF2 inhibition is a cause or a consequence of the resulting
DNA damage response. However, when TRF2 is removed in MEFs which also
lack the NHEJ component DNA Ligase IV, telomeres activate an ATM dependent
damage response, although the 3’ overhang is not removed79. Whether t-loops
still form in this setting would inform on their relative importance in preventing the
activation of ATM at telomeres.
The relative importance of the direct inhibition by TRF2 in preventing the
activation of ATM at the telomere could be addressed by construction of a
mutant of ATM which no longer interacts with TRF2. Fine mapping of the region
of ATM which interacts with TRF2 may allow the identification of point mutations
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which disrupt the ATM-TRF2 interaction without interfering with the function of
ATM in the DNA damage response. Expression of such a separation of function
mutant of ATM in AT cells would be expected to rescue the checkpoint functions
of ATM in response to IR, but would cause ATM to be activated specifically at
telomeres, if direct inhibition of ATM by TRF2 is required. If the DNA damage
response at telomeres is absent or not as robust in this setting, as when TRF2 is
removed completely, this would suggest that direct inhibition of ATM by TRF2 is
not the only mechanism by which TRF2 prevents ATM activation at telomeres.

A NOVEL PHOSPHORYLATION SITE IN TRF2, S368, IS POSITIVELY AND
NEGATIVELY REGULATED BY PIKKS
A novel phosphorylation site was detected in TRF2 with an antibody
against ATM phosphorylated on S1981, αATM-P. αATM-P detects TRF2
phosphorylated on S368 by western blot when TRF2 is overexpressed by
transient transfection in 293T cells. S368 is located in the flexible hinge domain
of TRF2, and is conserved immediately adjacent to the TIN2 binding site in both
human and mouse, raising the possibility that phosphorylation of TRF2 on S368
may influence the interaction between TRF2 and TIN2. S368 is conserved in all
known TRF2 proteins, including chicken and zebrafish, suggesting that it is
important for TRF2 function.
The regulation of TRF2 phosphorylated on S368 was studied by
overexpressing TRF2 by transient transfection in 293T cells. Because S368
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precedes a glutamine (Q) it represents a potential PIKK target. The PIKK
inhibitors, caffeine and wortmannin, both diminished TRF2 phosphorylation on
S368, indicating that S368 is positively regulated by (a) PIKK(s).
Phosphorylation of S368 was increased by UV radiation and HU treatment but
not IR, implicating the ATR kinase, the primary PIKK which responds to DNA
damage related to replication stress, as a positive regulator of the
phosphorylation. This was confirmed by siRNA mediated knockdown of ATR,
which reduced TRF2 phosphorylation on S368. Knockdown of ATM and DNAPK did not affect levels of TRF2 phosphorylated on S368. Unexpectedly,
overexpression of mTOR severely abrogated TRF2 S368 phosphorylation,
suggesting that mTOR may negatively regulate this phosphorylation event.
To our knowledge, the finding that mTOR may negatively regulate TRF2
phosphorylation on S368 is the only report of a connection between the mTOR
pathway and telomere biology. Such a connection is not entirely unexpected, as
telomeres are involved in regulating cell proliferation and mTOR controls cell
growth and proliferation in response to nutrient availability. Our findings indicate
that a systematic evaluation of the role of mTOR in telomere biology is called for.
The effect of mTOR on telomere length homeostasis could be analyzed by
inhibiting mTOR with rapamycin and following telomere length over time.
Similarly, whether mTOR influences telomere protection should be investigated.
Our attempts to find evidence of endogenous TRF2 phosphorylated on
S368 largely failed. Using the αATM-P antibody in western blot, we analyzed the
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lysates from many cell types in both human and mouse cells for evidence of
TRF2 phosphorylated on S368. Treatment of cells with a variety of DNA
damaging agents did not induce detectable levels of TRF2 phosphorylated on
S368. However, treatment of 293T cells with the alkylating agent MMS did
induce a band on the αATM-P western which could potentially represent TRF2
phosphorylated on S368. Unfortunately our attempts to immunoprecipitate TRF2
after MMS treatment to determine whether it was phosphorylated failed. We
were also unable to detect evidence of cell cycle specific phosphorylation of
TRF2 on S368.
Our inability to detect phosphorylation of endogenous TRF2 on S368
suggests that this form of TRF2 is normally present at extremely low levels; our
ability to detect the modification easily when TRF2 is expressed by transient
transfection in 293T cells is probably due to the extremely high levels of TRF2
overexpression achieved in this setting. Since our data indicates that TRF2 S368
phosphorylation is induced by replication stress and is positively regulated by the
ATR kinase, it is likely that only a small percentage of TRF2, perhaps only those
molecules in the immediate vicinity of a stalled replication fork, will be
phosphorylated on S368. Recently, a large scale study identified proteins which
are phosphorylated in response to IR by immunoprecipitation with SQ/TQ
phosphospecific antibodies followed by mass spectrometric analysis225. TRF2
was found to be phosphorylated on S368 in response to 10 Gy irradiation, the
first instance of ironclad evidence that endogenous TRF2 can be phosphorylated
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on S368. Contrarily, we were not able to detect phosphorylation of endogenous
TRF2 after IR nor did we see an increase in the phosphorylation of TRF2
expressed by transient transfection in response to IR. In our hands, TRF2
phosphorylation on S368 could only be induced by agents which cause DNA
replication stress. The discrepancy may be explained by the finding that IR can
secondarily activate ATR at the dose used by Matsuoka et al.158.

TRF2 S368 MUTANTS LOCALIZE TO TELOMERES AND FULFILL THE
MAJOR PROTECTIVE FUNCTIONS OF TRF2
The effect of mutation of S366 on the ability of TRF2 to protect the
telomere was analyzed by expressing TRF2 alleles with mutations at S366 in
TRF2F/- MEFs and removing endogenous TRF2 with Cre recombinase. TRF2
S366 mutants localized to telomeres and did not grossly impact the telomeric
localization of other shelterin components. The phosphorylation mutants
suppressed the telomeric deprotection phenotypes of TRF2 loss: TIF formation,
growth arrest, overhang removal, and telomere fusions. Furthermore, normal
rates of T-SCE were observed in cells expressing TRF2 S366 mutants, indicating
that the mutants protect telomeres from this form of homologous recombination.
However, loss of TRF2 only causes increased rates of T-SCE when Ku is also
deficient106, so the effect of TRF2 S366 mutants on T-SCE should also be
investigated in the Ku null setting.
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TRF2 S368 PHOSPHORYLATION AND TELOMERE LENGTH CONTROL
To study telomere length homeostasis in the presence of TRF2 S366
mutants, uncloned cell populations of TRF2F/- MEFs expressing S366 mutants
were exposed to Cre, and their telomere length was monitored over time. The
first time this experiment was performed, striking telomere elongation was
observed in the presence of TRF2 containing a phosphomimetic mutation at
position 366 (S366E). However, when the experiment was repeated, the
telomere length changes observed in the initial experiment were not reproduced
and telomere length in each cell population was relatively stable. It is possible
that an unidentified idiosyncrasy in cell culture conditions led to the observed
telomere lengthening in one experiment and not the other. It should be noted
that the role of TRF2 and other shelterin components in telomere length
regulation in mouse cells has not been studied to date. Therefore, there is little
knowledge on the behavior of MEF telomeres and effects of growth conditions on
their dynamics.
The effect of S366 mutation on telomere length was also examined in
human cells, which are a more established system for the study of telomere
length regulation than mouse cells. While overexpression of wildtype TRF2
caused the expected rapid telomere shortening, surprisingly, expression of TRF2
S368 mutants did not. However, this experiment has only been performed once
and it was also subsequently discovered that the construct used to express TRF2
S368E contained a cloning abnormality resulting in duplication of amino acids
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362-375. Telomere shortening due to overexpression of wildtype TRF2 may
occur by t-loop HR; our initial results suggest that TRF2 S368 mutants may be
unable to influence this process. T-loop HR requires the Mre11 complex member
Nbs1, raising the possibility that the observed inability of the S368 mutants to
promote t-loop HR is due to an impaired interaction with the Mre11 complex. We
have attempted to test the effect of mutation of S368 on the interaction between
TRF2 and the Mre11 complex, however difficulties in detecting the interaction at
all have prevented us from doing so. WRN and BLM are also TRF2 interacting
partners which could potentially be involved in the promotion of t-loop HR by
TRF2. However, it is unlikely that a decreased interaction between TRF2 and
WRN is responsible for the inability of TRF2 S368 mutants to influence t-loop HR,
because t-loop HR induced by TRF2ΔB expression was unaffected by WRN
deficiency (Wang and de Lange, unpublished).
Finally, the effect of ATR deficiency on telomere length homeostasis
should be investigated. No data is currently available regarding telomere length
in the absence of ATR, largely because loss of ATR function is incompatible with
life228. However, the existence of Seckel Syndrome, a disease in which patients
have low levels of functional ATR due to a mutation that affects splicing
efficiency252 indicates that it should be possible to severely deplete ATR protein
by shRNA mediated knockdown without killing cells, and telomere length could
be studied in this setting.
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TELOMERES ARE UNUSUALLY SENSITIVE TO REPLICATION STRESS
Unexpectedly, telomeres suffer a disproportionately large fraction of the
damage caused when replication forks are stalled with aphidicolin. In control
MEFs, over 25% of the 53BP1 foci induced by aphidicolin treatment colocalize
with telomeric DNA. Similar results have been obtained when human cells are
treated with aphidicolin (van Overbeek and de Lange, unpublished). Impaired
replication fork passage through the telomere could be due to several factors
(Fig. 5-1). As the fork progresses through telomeric DNA, and single-stranded
DNA forms, G quadruplex structures may form on the G rich strand. A replication
block of this nature is expected to lead to uncoupling of replicative helicases and
polymerases, exposure of large amounts of single-stranded DNA, and activation
of the ATR checkpoint pathway. A second possibility is that shelterin itself acts
as a barrier to the passage of the replication fork, and may need to be removed
or modified in order for the fork to pass. If shelterin does hinder the passage of
the replication fork, it may function in a similar manner to the RFBs formed within
rDNA repeats of budding yeast by the binding of the Fob1 protein (discussed in
the introduction to Chapter 4). This type of replication fork blockage does not
lead to the generation of large amounts of single-stranded DNA246 and does not
appear to require the ATR pathway for fork stabilization247. Consistent with nonreliance on the ATR pathway, which acts to prevent recombination at stalled
replication forks, introduction of a RFB into an ectopic site in the S. pombe
genome led to increased rates of intrachromosomal recombination247.
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Fig. 5-1: Two models for replication fork hindrance in telomeric DNA
(A) G quadruplex formation on the G rich strand would be expected to cause stalling of the replicative
polymerases on the lagging strand. Continued unwinding by the replicative helicases would lead to the
creation of single-stranded DNA which can be bound by RPA and activate the ATR checkpoint pathway.
(B) Blockage of the replication fork by shelterin is not expected to lead to the generation of single-stranded
DNA and the activation of the ATR checkpoint pathway. In a poorly understood process, this type of
proteinacious replication block leads to increased recombination at the stalled fork.

To distinguish between these two possibilities for the basis of the
replication sensitivity of telomeres, recombination at telomeres after aphidicolin
treatment could be examined. If the telomeric sensitivity to replication stress is
due to Q quadruplexes leading to the uncoupling of replicative helicases and
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polymerases, the ATR pathway would be activated and downregulate
recombinogenic events at telomeres. If shelterin is the primary culprit, elevated
levels of recombination at telomeres would be expected. Also in this case,
overexpression of shelterin would be expected to increase the sensitivity of
telomeres to aphidicolin and increase levels of telomeric recombination events.
In human cells, aphidicolin treatment leads to an increased frequency of TSCE detected by CO-FISH (van Overbeek and de Lange, unpublished) indicating
that collapsed forks within telomeres are repaired by HR between sister
chromatids and suggesting that shelterin is at least partially responsible for the
hindrance of replication forks in telomeric DNA. It remains to be determined
whether a similar outcome occurs in mouse cells. However, even if the elevated
levels are of HR also occur at mouse telomeres after exposure to aphidicolin, it is
impossible to rule out a contribution of G quadruplex formation to the aphidicolin
sensitivity of telomeres. This would need to be investigated more directly by
examining single-stranded DNA formation and the activation of the ATR pathway
specifically at telomeres after aphidicolin treatment. Furthermore, if the
aphidicolin sensitivity is due to G quadruplex formation, overexpression of the
RecQ helicases WRN and BLM would be predicted to ameliorate the sensitivity,
while their genetic deletion would exacerbate it. We have shown that expression
of an allele of TRF2 containing a phosphomimetic mutation at a site known to be
positively regulated by ATR, partially relieves replication stress induced by
aphidicolin at the telomere. This finding is strongly suggestive that the ATR
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pathway is active at telomeres under conditions of replication stress, and that an
ATR dependent pathway is at least partially responsible for the elevated
sensitivity of telomeres to aphidicolin.
Our findings have shown that telomeres are exquisitely sensitive to
replication stress induced by aphidicolin. However, aphidicolin has been used to
synchronize cells and study telomeres during specific phases of the cell cycle.
For example, it was shown in aphidicolin synchronized cells that several factors
indicative of DNA repair activities and replication fork restart, including Rad1 and
Rad17, localize to telomeres during S phase20. These findings should be
interpreted with caution, as they may be a result of aphidicolin induced damage
and not representative of normal replication of telomeres during S phase, as the
authors have surmised. Alternative methods of cell synchronization that do not
rely on drugs which cause replication stress, such as centrifugal elutriation and
contact inhibition and release, should be employed when possible.

TRF2 PHOSPHORYLATION ON S366 MAY RELIEVE REPLICATION STRESS
AT THE TELOMERE
Because phosphorylation of TRF2 on S368 is mediated by ATR and is
induced by replication stress, we analyzed the effect of TRF2 S366 mutants on
the telomeric response to replication stress. Surprisingly, we found that
expression of TRF2 containing a phosphomimetic mutation at position 366, TRF2
S366E, improved cellular survival after aphidicolin treatment. We also found that
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cells expressing TRF2 S366E had fewer chromatid breaks and 53BP1 foci after
treatment with aphidicolin.
In spite of having a genome wide effect, several lines of evidence indicate
that TRF2 S366E mitigates the deleterious effects of aphidicolin treatment by
relieving replication stress at the telomere. Increased survival and decreased
chromatid breaks and 53BP1 foci were demonstrated in two independent clonal
cell lines. In both cell lines TRF2 S366E is expressed at similar levels as
endogenous TRF2 and localizes primarily to telomeres. Additionally, in the
presence of TRF2 S366E, the percentage of aphidicolin induced 53BP1 foci
which localized to telomeres was decreased by a small but significant amount.
We believe it is likely that by relieving replication stress specifically at the
telomere, TRF2 S366E improves the outcome of aphidicolin treatment for the
whole genome. We propose that the great number of stalled forks at telomeres
caused by aphidicolin treatment acts as a sink for replication fork processing
factors. This telomeric sink would enhance the effect of aphidicolin on the rest of
the genome, increasing the frequency of fork stalling, and also increasing the
likelihood that stalled forks will not be reinitiated, and so will form DSBs. If this is
true, factors involved in sensing and processing stalled replication forks including
ATR, ATRIP, Rad17, the 9-1-1 complex, WRN, and BLM, should be abundant at
telomeres after aphidicolin treatment. Furthermore, cells with shorter telomeres
should exhibit enhanced survival after aphidicolin treatment, compared with cells
with longer telomeres.
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At least two factors may contribute to poor replication fork processivity in
telomeric DNA: the tendency of the G rich strand to form G quartets when singlestranded and the potential of shelterin binding to hinder the passage of the
replication fork. Phosphorylation of TRF2 on S368 could potentially address both
of these issues. For example, phosphorylation of S368 could allow TRF2 to bind
and recruit a factor which resolves G quartets. Excellent candidates for such a
factor are the RecQ helicases, WRN and BLM, known interacting partners of
TRF2, which can resolve G quartets and also may play a role in the reinitiation of
stalled replication forks. Secondly, phosphorylation of TRF2 on S368 could
modify the conformation of shelterin so that the replication fork can more easily
pass through telomeric DNA. We have demonstrated that a phosphomimetic
mutation at position 368 decreases the TRF2-TIN2 interaction. Because TIN2
also interacts with TRF1, decreased interaction with TRF2 is not expected to
result in loss of TIN2 at telomeres. Accordingly, ChIP data indicates that TIN2 is
not significantly decreased at telomeres in the presence of TRF2 S366E.
However, a weakened interaction between TRF2 and TIN2 has the potential to
affect the conformation of the entire shelterin complex, because in addition to
TRF2, TIN2 binds TRF1 and TPP1. Therefore, phosphorylation of TRF2 on
S368, by weakening the interaction between TIN2 and TRF2, could “loosen” the
conformation of the shelterin complex, allowing the replication fork to more easily
pass.
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If expression of TRF2 S366E relieves replication stress at the telomere,
expression of TRF2 S366A is expected to heighten the sensitivity of telomeres to
replication stress. For example, in the models discussed above, TRF2 S366A
would be expected to exhibit reduced interaction with RecQ helicases and
increased binding with TIN2. However, in general, we observed that expression
of TRF2 S366A did not greatly alter telomeric sensitivity to replication stress. It is
possible that under conditions of replication stress, several components of
shelterin are phosphorylated by ATR and act in concert to relieve replication
stress at the telomere. This would reduce the impact of mutation of any single
site within shelterin. In fact, there are conserved potential PIKK targets (SQ/TQ
motifs) in many shelterin componenets including TRF1, Rap1, and TIN2.
Exploration of the regulation of the phosphorylation of these additional sites and
their role in the replication of telomeric DNA is of immediate interest.

PHOSPHOSPECIFIC ANTIBODIES DIRECTED AGAINST SQ/TQ MOTIFS
HAVE A TENDENCY TO CROSS-REACT WITH PHOSPHOPROTEINS OTHER
THAN THEIR INTENDED TARGETS
In the course of our studies, we have documented several instances
where antibodies targeting phosphorylated SQ/TQ motifs within specific proteins
cross-react with phosphoproteins other than their intended targets. By western
blot, the antibody targeting ATM phosphorylated on S1981, αATM-P, detects
TRF2 phosphorylated on S368 and at least one other protein that is
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phosphorylated in response to DNA damage. Furthermore, two antibodies
targeting different SQ/TQ motifs in TRF2 detect a protein other than TRF2 in
DNA damage foci. Recently it was shown that SQ/TQ specific antibodies readily
immunoprecipitate phosphoproteins other than their intended targets225. These
findings indicate that antibodies against phosphorylated SQ/TQ motifs should be
used with caution and stringent controls are required to confirm the identity of the
detected protein. Additionally, studies which have utilized this type of antibody
need to be re-evaluated to consider the possibility of cross-reaction.
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Materials and Methods
Cell culture
IMR90 primary lung fibroblasts (ATCC), HeLa subclones 1.3 and 204, p53-/- and
SV40 transformed MEFs, 293T cells, Phoenix ecotropic and amphotrophic
packaging cell lines, and GM847 cells were grown in DMEM supplemented with
100 U/ml penicillin (Sigma), 0.1 µg/ml of streptomycin (Sigma), 2.0 mM Lglutamine (Invitrogen), 0.1 mM non-essential amino acids (Invitrogen), and 10%
Fetal Bovine Serum. BJ fibroblasts (Clontech) were grown in 4:1 DMEM/199
media supplemented with 15% fetal bovine serum, 100 U/ml penicillin (Sigma),
0.1 µg/ml of streptomycin (Sigma), 2.0 mM L-glutamine (Invitrogen), 0.1 mM nonessential amino acids (Invitrogen), and 1 mM sodium pyruvate (Sigma). All cells
were grown at 37°C, 5% CO2, and 95% relative humidity. Cells were passaged
by pre-rinsing with room temperature Trypsin-EDTA (Gibco, 0.25%) followed by
incubation in Trypsin-EDTA for 2-5 min. Cells were seeded as indicated in text.
Cells were counted with a Counter Counter Z1 Particle counter. For growth
curves, 300,000 cells were plated on a 10 cm dish and grown for 72 hrs. Cells
were harvested using trypsin and recovered in 4 ml of media, and the total cell
number was determined. 300,000 cells were plated in a new 10 cm dish. At
specified times, extra cells were plated in order to obtain protein and DNA
samples for analysis. Population doublings were determined by the following
formula: PD = original PD + [ln(# cells at passage/#cells seeded)/ln(2)] using
Excel.
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Radiation and drug treatment of cells
For γ-irradiation, cells were seeded in 6 cm culture dishes and exposed to a Ce137
source. Cells were allowed to recover in the incubator for the indicated amount
of time before harvesting. For UV radiation, media was removed and reserved.
Cells were subjected to the indicated dose of UV radiation in a Stratalinker 1800
(Stratagene). Reserved media was added back to cells and cells were allowed to
recover in the incubator for the indicated amount of time before harvesting. Cells
were treated with the indicated amounts of aphidicolin (Sigma), caffeine (Sigma),
wortmannin (Sigma), Okadaic Acid (Sigma), MMS (Sigma), hydroxyurea (Sigma),
and rapamycin (Calbiochem) for the indicated amounts of time. After treatment,
MMS was neutralized with an equal volume of 10% sodium thiosulfate for 5 min.
Calcium phosphate transfection of 293T cells
One day prior to transfection, 1 x 106 293T cells were plated in 10 cm dishes.
Cells were transfected with 10 μg of the appropriate plasmid using CaPO4
coprecipitation. For each plate, 428 μl H20, 62 μl 2M CaCl2, and 10 μg plasmid
DNA was mixed with an equal amount of 2X HBS (50 mM HEPES pH 7.05, 10
mM KCl, 12 mM dextrose, 280 mM NaCl, 1.5 mM Na2PO4) while being mixed by
blowing air through a 2 mL pipette with a Pipet-aid (Drummond). Media was
refreshed 5-8 hrs. after transfection. 48 hrs. after transfection, cells were
harvested in media, counted, washed with PBS, and resuspended in 200-500 μl
of lysis buffer (50 mM Tris-HCl pH 7.4, 1% Triton X-100, 0.1% SDS, 150 mM
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NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, with a complete mini-protease
inhibitor tablet [Roche] per 10 ml). The NaCl concentration was raised to 400
mM, and the lysate was incubated on ice for 20 min. The NaCl concentration was
reduced to 200 mM with an equal volume of cold water, cell debris was removed
by centrifugation at 13K for 10 min. at 4°C. 4X Laemmli buffer (0.24 mM TrisHCl, 4% SDS, 20% glycerol, 10% beta-mercaptoethanol, 0.004% bromophenol
blue) was added to the lysate at a ratio of 1:3. Samples were boiled for 5 min.
Immunoprecipitations
For immunoprecipitation of proteins expressed by transient transfection in 293T
cells, transfection and harvesting was performed as above. 50 μL of 2X Laemmli
buffer was added to 50 μL of lysate and set aside as the “Input.” Antibody (2 μL
of affinity purified and commercial antibodies, 10 μL of crude serum) was added
to 400 μL of lysate. Samples were nutated at 4°C for 5 hrs. 60 μL of a Protein G
sepharose slurry (50% [v/v] Protein-G sepharose [Amersham] in PBS in 1 mg/ml
BSA) were added and samples were nutated at 4°C for an additional 60 min.
Beads were washed 3 times at 4°C with lysis buffer, and immunoprecipitated
protein was eluted with 60 μL 2X Laemmli buffer. For immunoprecipitation of
endogenous ATM from IMR90 fibroblasts for the phosphorylation assay, cells
were resuspended in lysis buffer (50 mM Hepes pH 7.5, 150 mM NaCl, 50 mM
NaF, 1% Tween-20, 0.2% NP40, 1mM PMSF, with 1 complete mini-protease
inhibitor tablet [Roche] per 10 mL) and centrifuged at 13K rpm for 10 min. 400 μl
of lysate was incubated with 30 μl of blocked protein G beads and 100 μl of
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D16.11 monoclonal supernatant. Beads were washed once in lysis buffer and
twice in RIPA buffer and resuspended in 60 μl of 2X Laemmli buffer. To
generate Protein G sepharose slurry, 3-4 mL of beads were centrifuged at 1K for
1 min. at 4°C, supernatant was removed, and beads were washed with PBS 3
times. Beads were resuspended with an equal volume of 5% BSA in PBS and
nutated at 4°C for 1 hr. Sodium azide was added to 0.02% and beads were
stored at 4°C.
Retroviral gene delivery
One day prior to transfection, 1 x 106 Phoenix packaging cells (293T derived cell
lines) were plated in 10 cm dishes. For infection of mouse cells, Phoenix
ecotropic cells were used. For infection of human cells, Phoenix amphotropic
cells were used. Phoenix cells were transfected with 20 μg of the appropriate
plasmid DNA by CaPO4 coprecipitation (described above). The media was
refreshed 5-8 hrs. later, and again 24 hrs. later. 36 hrs. after transfection, media
was filtered through a 0.4 μm filter and polybrene was added to a final
concentration of 4 μg/mL. Fresh media was added to the virus producing cells.
This procedure was repeated 3 additional times at 12 hr. intervals. If appropriate,
12 hrs. after the final infection, fresh media was added containing antibiotics for
selection (puromycin 2 μg/ml, hygromycin 90 μg/ml) for 4-5 days until uninfected
control cells were completely dead.
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Lentiviral gene delivery
293T cells were transfected using calcium phosphate with 3 μg each of helper
plasmids (pMDLg/RRE, pRSV-rev, and pCMV-VSVG) and 7 μg of lentiviral vector
(pLenti6/Ubc/V5, Invitrogen) carrying the appropriate transgene per 10 cm dish.
Fresh media was added 5-8 hrs. after transfection. 72 hrs. after changing the
media, virus-containing media was collected in a 50 ml conical tube and
centrifuged for 5 min. at 1K rpm at 4°C. The virus was filtered through a 0.4 μm
filter and polybrene was added to a final concentration of 4 μg/ml. 2x105 MEFs
were plated for each infection, the day before infection. Half of the filtered virus
was used for the initial infection. Remaining virus was kept on ice and used for a
second infection 12 hrs. later. 12 hrs. after the second infection, virus containing
medium was replaced with fresh medium. The following day, media was
replaced with media containing 6 μg/ml blasticidin. After four days of selection,
blasticidin concentration was dropped to 2.5 μg/ml and cells were selected for an
additional 7 days.
Isolation of clonal lines
TRF2f/- MEFs expressing TRF2 alleles (not exposed to Cre) were plated at low
density (500-2000 cells/10 cm dish) and grown for approximately 2 weeks until
clonal populations were visible under the light microscope. Clonal populations of
cells were isolated by trypsinizing cells in cloning cylinders. Clonal populations
were transferred to a well of a 96 well plate. When the cells reached confluence
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in the well, the clonal population was expanded.
Expression of Cre Recombinase
Cre was introduced into MEFs using pMMP Hit & Run Cre-GFP retrovirus253 or
pWZL-Cre retrovirus (containing the hygromycin resistance gene) using the
retroviral infection technique described above.
Whole cell lysates and western blots
For whole cell lysates, cells were harvested, washed with PBS, counted and
resuspended in 2X Laemmli buffer at a concentration of 5000 cells/μl. Lysates
were boiled for 5 min. and DNA was sheared through a 28 gauge insulin syringe.
Protein samples were separated by SDS-PAGE and blotted onto nitrocellulose
membranes. Membranes were blocked in 10% milk in PBST (0.5% Tween-20 in
PBS) for 30 min. at RT and nutated with primary antibodies in 0.1% milk in PBST
overnight at 4°C. Membranes were washed 3 times in PBST, nutated in
secondary antibody in 0.1% milk in PBST for 45 min. at RT, and washed 3 times
with PBST at RT. ECL (Amersham) was applied to membranes for 5 min. before
exposure to film.
Synchronization of HeLa cells
0.5 x 106 HeLa cells were plated in a 10 cm culture dish and treated with 2 mM
thymidine 24 hrs. later. After 14 hrs., cells were washed 3 times with prewarmed PBS and fresh medium was added. 11 hrs. later, thymidine was added
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to a final concentration of 2 mM. After 15 hrs., cells were washed with prewarmed PBS and again provided with fresh media. Cells were harvested at the
indicated time points for western blot and FACs analysis. Exponentially growing
HeLa S3 cells (suspension culture) were fractionated by size using centrifugal
elutriation in an Avanti J-20 XP Centrifuge (Beckman) 11 fractions were
obtained and processed for western blot and FACs analysis alongside
unfractionated cells.
Fluorescence activated cell sorting (FACS) analysis
Cells were harvested from a 10 cm dish by trypsinization, washed with PBS, and
resuspended in 100 μl PBS. Two ml ice cold 70% ethanol was added dropwise
while vortexing. Cells were stored at 4°C. For FACS, cells were resuspended in
propidium iodide solution (500 μl PBS, 100 μg RNase, 25 μg propidium iodide)
and incubated at RT for 30 min. Cells were analyzed on a Becton Dickinson
FACS – Scan II.
Immunofluorescence
Cells were plated in dishes on coverslips. Cells were rinsed with PBS, fixed with
2% paraformaldehyde in PBS for 10 min. at RT, wash twice with PBS for 5 min.
Cells were either stored in PBS with the addition of 0.02% azide or processed
immediately. Cells were permeabilized with 0.5% NP40. If extraction was
desired, prior to fixation, cells were treated with Triton X-100 extraction buffer
(0.5% Triton X-100, 20 nM HEPES-KOH pH 7.9, 50 mM NaCl, 3 mM MgCl2, 300
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mM sucrose). Extracted cells were fixed with 3% paraformaldehyde, 2% sucrose
for 10 minute at RT, and washed twice with PBS. If extraction was performed,
Triton X-100 buffer was used for permeabilization instead of 0.5% NP-40. After
permeabilization, cells were washed three times with PBS and blocked with PBG
(0.2% (w/v) cold water fish gelatin (Sigma), 0.5% (w/v) BSA (Sigma) in PBS) for
30 min. at RT. Cells were incubated with primary antibody diluted in PBG
overnight at 4°C, washed 3 times with PBG at RT, incubated with secondary
antibody diluted 1:250 in PBG for 45 min. at RT, and washed 3 times with PBS.
To the second PBS wash 0.1 μg/ml 4,6-diamidino-2-phenylindole (DAPI) was
added. Coverslips were sealed onto glass sides with embedding media
(ProLong Gold Antifade Reagent, Invitrogen).
Microscopy and image processing
Images were captured using an Axioplan II Zeiss microscope with a Hamamatsu
CCD digital camera using Improvision OpenLab software. Images were merged
in OpenLab and processed with Adobe Photoshop.
Differential salt extraction
Cells were harvested by trypsinization, washed twice in serum-containing media,
and once with cold PBS. Cells were resuspended in 10 times the pellet volume
of Buffer C-150 (20 mM HEPES pH 7.9, 25% glycerol, 5 mM MgCl, 0.2% NP-40,
1 mM DTT, 1 mM PMSF, with a complete mini-protease inhibitor tablet [Roche]
per 10 ml). Lysates were incubated for 15 min. on ice and then the samples
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were centrifuged for 5 min. at 3K rpm at 4°C. The supernatant is the 150 mM
fraction and represents the soluble cytoplasmic and nucleoplasmic proteins.
Pellets were resuspended in Buffer C-420 (Same as Buffer C-150 but contains
420 mM KCl) and incubated on ice for 15 min. Samples were centrifuged for 10
min. at 14K rpm at 4°C. The supernatant is the 420 mM fraction and contains
chromatin bound proteins. The final pellets were resuspended in 2X Laemmli
buffer and sonicated.
Preparation of genomic DNA
Cells were harvested by trypsinization and washed with PBS. 0.5 X 106 cells for
MEFs and 1 x 106 cells for HeLa cells were resuspended in 50 μl PBS and
incubated at 50°C for 5 min. Using pipette tips with the ends cut off, 50 μl of 2%
agarose (prewarmed to 50°C) was added to each sample, mixed, and incubated
for 5 min at 50°C. The 100 μl mixture was added to the Bio-Rad plug cast,
incubated at RT for 5 min. and at 4°C for 15 min. Solidified plugs were incubated
in 0.5 ml Proteinase K digestion buffer (10 mM Tris-HCl pH 7.9, 250 mM EDTA
pH 8.0, 0.2% sodium deoxycholate, 1% sodium lauryl sarcosine, and 1 mg/ml
fresh Proteinase K) overnight at 50°C. Plugs were washed three times with TE
for one hr. each at RT with nutation. Plugs were washed for 1 additional hr. at
RT with TE containing 1 mM PMSF and stored at 4°C in this final wash. Prior to
digestion, plugs were washed for 1 hr. in fresh TE and 20 min. in H20. Plugs
were equilibrated for 1 hr. in the appropriate restriction enzyme buffer at RT.
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Each plug was then digested with 60 units of MboI for MEFs and 60 units of MboI
and 60 units AluI for human cells overnight at 37°C. Plugs were washed with TE
for 1 hr. and equilibrated in 0.5X TBE for 30 min.
In gel hybridization to detect telomeric DNA from MEFs
DNA from MEFs was fractionated on a CHEF-DRII PFGE (Biorad) in a 1%
agarose gel in 0.5X TBE for 24 hrs. at 6 V/cm at 14°C. Gels were stained with
ethidium bromide and photographed. Gels were dried and then prehybridized in
Church Mix (0.5M Na2HPO4 pH 7.2, 1 mM EDTA, 7% SDS, 1% BSA) for 1 hr. at
50°C. Hybridization was performed overnight at 50°C in Church Mix with 4 ng of
a γ-32P-ATP end-labeled probe, [CCCTAA]4 (See below for labeling protocol).
The gel was washed at 55°C: 3 times for 30 min. each in 4X SSC and one time
for 30 min. in 4X SSC, 0.1% SDS and exposed to a PhosphorImager screen.
Subsequently, the gel was denatured in 0.5 M NaOH, 1.5 M NaCl for 30 min.,
neutralized with two 15 minute washes in 0.5 M Tris-HCl pH 7.5, 3 M NaCl,
prehybridized in Church mix for 1 hr. at 55°C, and hybridized with the same
probe as above overnight at 55°C. The gel was washed and exposed as above.
Southern blot to detect telomeric DNA from human cells
DNA was separated on a 0.7% agarose gel in 0.5X TBE with ethidium bromide
by running for 1 hr. at 30 V and then running until the orange G front was at the
bottom of the gel (approximately overnight at 45V). Gel was photographed. Gel
was then run until the 1.3 kb marker was almost at the bottom of the gel. Gel
146

was photographed with a ruler next to the markers. Gel was gently shaken in
Depurination solution (0.25M HCl) for 30 min., Denaturation solution (1.5 M NaCl;
0.5 M NaOH) for 30 min. twice, and Neutralization solution (1 M Trish pH 7.4,
1.5M NaCl) for 30 min. twice. Gel was then blotted onto a Hybond filter overnight
in 20X SSC. Blot was cross-linked, rinsed in H20, and prehybridized and probed
as in the in gel hybridization protocol above.
Chromatin Immunoprecipitation (ChIP)
Cells were washed with PBS, fixed in 1% formaldehyde in PBS for 60 min. at RT,
washed in PBS, and lysed in 1% SDS, 50 mM Tris-HCl pH 8.0, 10 mM EDTA at a
density of 1x107 cells/ml. Lysates were sonicated on ice for 10 cycles of 20
seconds each (0.5 seconds on/0.5 seconds off) on power setting 5 on a Misonix
Sonicator 3000. Two 50 μl aliquots of lysates were set aside at 4°C to represent
“Total” DNA. 200 μl of lysate was diluted with 1.2 ml 0.01% SDS, 1.1% Triton X100, 1.2 mM EDTA, 16.7 mM Tris-HCl pH 8.0, and 150 mM NaCl. Antibody (20
μl crude serum or 4 μl affinity purified antibody or anti-c-myc 9E10, see antibody
section below for specifics) was added and cells were nutated overnight at 4°C.
30 μl protein G sepharose beads (Amersham; blocked with 30 μg BSA and 5 μg
sheared E. coli DNA) was added and samples were nutated for an additional 30
min. at 4°C. Beads were pelleted by centrifugation and pellets were washed with
0.1% SDS, 1% Triton X-100, 2 mM EDTA pH 8.0, 20 mM Tris-HCl pH 8.0, 150
mM NaCl. The second wash was the same except with 500 mM NaCl.
Subsequent washes were with 0.25 M LiCl, 1% NP-40, 1% Na-deoxycholate, 1
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mM EDTA pH 8.0, 10 mM Tris-HCl pH 8.0, 1 mM EDTA. Chromatin was eluted
from beads with 500 μl 1% SDS, 0.1M Na2CO3. 450 μl 1% SDS, 0.1M Na2CO3
was added to the “Total” fractions, and these were subsequently processed along
with the rest of the samples. 20 μl 5M NaCl was added and samples were
incubated for 4 hr. at 65°C to reverse cross-links. At this point, 20 μl 1M Tris-HCl
pH 6.5, 10 μl 0.5 M EDTA, and 20 μg DNase free RNase A was added and
samples were incubated at 37°C for 30 min. 40 μg proteinase K was added and
samples were digested for 60 min. at 37°C and extracted with phenol. 20 μg of
glycogen was added and samples were mixed. 1 ml ethanol was added and
DNA was precipitated overnight at -20°C. Precipitated DNA was dissolved in 100
μl H20, denatured at 95°C for 5 min., and blotted onto Hybond membranes in 2X
SSC (0.3M NaCl, 0.03M Sodium citrate). “Total” fractions were diluted 1/4, 1/8,
and 1/16 and blotted as well. Membranes were treated with 1.5M NaCl, 0.5 N
NaOH for 10 min. and then with 1 M NaCl, 0.5 M Tris-HCl pH 7.0 for 10 min.
Hybridization was performed with a γ32-P endlabeled [CCCTAA]4 probe as
described for in gel hybridization of genomic DNA. Membranes were washed 4
times in 2X SSC and exposed overnight to a PhosphorImager screen. Screens
were developed using a STORM 820 Phosphorimager (Molecular Dynamics).
ImageQuant software was used to quantify the percent of total telomeric DNA
that was precipitated by each antibody.
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γ-32P end labeling of oligonucleotides with T4 polynucleotide kinase (PNK)
2 μl H20, 1 μl 10X T4 DNA PNK buffer (NEB), 1 μl 10 U/μl T4 DNA PNK (NEB), 1
μl 50 ng/μl [CCCTAA]4 oligonucleotide and 5 μl 10.0 mCi/ml γ-32P (NEN) were
mixed and incubated for 45 min. at 37°C. 80 μl TES (10 mM Tris-HCl pH 8.0, 10
mM EDTA pH 8.0, 0.01% SDS) were added to stop the reaction. The probe was
loaded onto a 3 ml G25 Sephadex column equilibrated with TNES (10 mM TrisHCl pH 7.4, 10 mM EDTA, 100 mM NaCl, 1% SDS). The column was washed
with 700 μl TNES and the probe was eluted with 600 μl TNES.
Metaphase spreads
Cells were grown to approximately 40% confluence on 10 cm dishes and
incubated for 1-2 hrs. in 0.1 μg/ml colcemide (Sigma). Cells were harvested by
trypsinization, centrifuged at 1K for 5 min., and resuspended in 0.075M KCL
prewarmed to 37°C. Cells were incubated at 37°C for 15 min. with occasional
inversion. Cells were centrifuged at 1K for 5 min. and supernatant was decanted.
Cells were resuspended by tapping in the remaining (~200 μl) supernatant. 500
μl of cold 3:1 methanol:glacial acetic acid fixative was added dropwise while cells
were mixed gently on a vortexer (<1000 rpm). Another 500 μl fixative was added
slowly while cells were being mixed. Tubes were then filled to 10 mL with the
fixative and stored at 4°C overnight or longer. Cells were centrifuged at 1K rpm
for 5 min. and supernatant was decanted. Cells were resuspended in the
remaining fixative (~300 μl) and dropped from approximately 6 inches onto glass
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slides which had been soaked in cold water. Slides were washed with fresh
fixative and placed on a humidified heating block set to 70°C (42°C for CO-FISH)
for 1 minute. Spreading efficiency was checked under a light microscope. Slides
were dried overnight. If only DAPI staining was required, slides were rehydrated
in PBS for 5 min., stained with DAPI in PBS for 5 min., washed in PBS for 5 min.,
and allowed to dry before mounting.
CO-FISH
For CO-FISH cells were grown in the presence of BrdU:BrdC (3:1, 10 μM final)
for 12-14 hrs. and supplemented with 0.1 μg/ml colcemide (Sigma) for the final
two hrs. Metaphases were harvested as described above. Cells were treated
with 0.5 mg/ml RNase A (in PBS, DNase free) for 10 min. at 37°C. Slides were
then stained with 0.5 μg/ml Hoechst 33258 (Sigma) in 2X SSC for 15 min. at RT.
Slides were then exposed to 365-nm UV light in a Stratalinker 1800 UV irradiator
for 30 min. (equivalent to 5.4x103 J/m2). Strands which had incorporated BrdU
and BrdC were digested with 80 μl of 10 units/μl Exonuclease III (Promega)
under a coverslip for 10 min. at RT. Exonuclease III digestion was repeated.
Slides were washed in PBS and dehydrated in an ethanol series: 5 min. each
70%, 85%, 100%, and air dried. Slides were incubated with the TAMRA-TelG 5'[TTAGGG]3-3' PNA probe (Applied Biosystems) diluted 1:5000 in 80 μl of
hybridization mix (10 mM Tris-HCl pH 7.2, 70% deionized formamide, 0.5%
blocking reagent [Boehringer Mannheim]) under a coverslip for two hrs. at RT in
the dark. Slides were washed for several seconds in Wash I (70% formamide, 10
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mM Tris-HCl pH 7.2, 0.1% BSA). Slides were incubated with the FITC-TelC 5'[CCCTAA]3-3' PNA probe (Applied Biosystems) in hybridization mix as described
above. Slides were washed in Wash I twice for 30 min. each with a stir bar on a
magnetic stir plate. Slides were then washed three times for 5 min. each in
Wash II (0.1M Tris-HCl pH 7.2, 0.15M NaCl, 0.08% Tween-20) with a stir bar on
a magnetic stir plate. DAPI was added to the second wash. Slides were
dehydrated in an ethanol series: 5 min. each 70%, 95%, 100%, air dried, and
mounted.
FISH
FISH was performed according to the same protocol as CO-FISH with the
following exceptions. Cells were not incubated with BrdU/BrdC prior to collection
of metaphase spreads. After metaphase spreads were dropped, slides were
placed on a heating block set to 70°C (not 42°C as for CO-FISH). Hybridization
was only performed with the FITC-TelC 5'-[CCCTAA]3-3' PNA probe at 1:1000
and slides were placed on a heating block set to 80°C for 3 min. to denature
DNA.
IF-FISH
Cells were plated in dishes with coverslips. Cells were rinsed with PBS, fixed
with 2% paraformaldehyde in PBS for 10 min. at RT, washed twice with PBS for
5 min. each. Cells were either stored in PBS with the addition of 0.02% azide or
processed immediately. Coverslips were blocked for 30 min. in blocking solution
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(1 mg/ml BSA, 3% goat serum, 0.1% Triton X-100, 1 mM EDTA in PBS) and
incubated for 1 hr. in primary antibody diluted in blocking solution. Cover slips
were washed 3 times 5 min. each in PBS before incubation in secondary
antibody diluted in blocking solution. Cover slips were washed 3 times 5 min.
each in PBS, dehydrated in an ethanol series: 5 min. each 70%, 95%, 100%,
and air dried. Coverslips were transferred (cells facing up) to glass slides and 80
μl of FITC-TelC 5'-[CCCTAA]3-3' (Applied Biosystems) probe at 1:1000 in
hybridizing solution (70% formamide, 0.5% blocking reagent [Boehringer
Mannheim], 10 mM Tris-HCl pH 7.2) was added. Slides were placed on a
heating block set to 70°C for 5 min. and incubated in the dark for 2 hrs. –
overnight. Coverslips were washed twice for 15 min. in 70% formamide, 10 mM
Tris-HCl pH 7.2 and three times for 5 min. in PBS. DAPI was added to the
second PBS wash. Cover slips were sealed on glass slides with embedding
media.
siRNA Treatment
Dharmacon ON-TARGETplus SMARTpool siRNA against ATR or Dharmacon
luciferase siRNA (5’-CGTACGCGGAATACTTCGA-3’) and TRF2 were
cotransfected into 293T cells using DharmaFECT Duo transfection reagent
according to the manufacturer’s instructions. 0.5 x 106 293T cells were plated
per 6 cm dish the day before transfection. For each 6 cm dish: 5 μl of 1μg/μl
TRF2 plasmid DNA, 25 μl 20 μM siRNA and 470 μl DMEM (with no serum or
supplements) were mixed gently in one tube. In a second tube, 30 μl of
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DharmaFECT Duo transfection reagent were mixed with 470 μl DMEM (with no
serum or supplements). The two tubes were incubated at RT for 5 min. The
contents of the two tubes were then mixed together and incubated at RT for 20
min. 4 ml of antibiotic-free media (containing serum and other supplements) was
added to the 1 ml transfection mixture. Cells were rinsed once with antibiotic free
media and then the media containing the transfection mixture was added. Cells
were harvested 48 hrs. after transfection (or at timepoints indicated in text) as
described above for cells transfected by calcium phosphate co-precipitation.
shRNA
Oligonucleotides targeting PIKKs were designed by Agnel Sfeir and were
obtained from E-oligos, annealed, phosphorylated and cloned into pSuperiorPURO (Oligoengine). Plasmids were sequenced to confirm integrity of the
construct. pSuperior-Puro shRNA containing constructs were used to retrovirally
infect 293T cells as described above. Subsequent to selection, infected cells
were transfected with TRF2 using the calcium phosphate method as described
above.
shRNAs were designed to target a 19 nucleotide sequence within the gene of
interest in the following format:
sense: 5’-GATC4(19mer)T2CA2GAGA(19mer reverse complement)T5G2A4-3’
antisense: 5’-AGCT4C2A5(19mer)TCTCT2GA2(19mer reverse complement)G2-3’
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ATM
1 – GGACTTGTTGAAATACTTA
2 – CGAGATCCTGAAACAATTA
3 – CCAGATGTGTAATACATTA
DNA-PK
1 – GATCGCACCTTACTCTGTT
2 – GCATCTCTTGCCTTTAATA
3 – GCATCCAGCTAAACCTAAA
SMG1
1 – CCAGGACACGAGGAAACTG
2 – GCAGCTGGATTCCATTTAA
3 – GCATCACAGGATAGCAATA
Aphidicolin survival assay
MEFs expressing TRF2 alleles and control MEFs were infected with the pWZLCre retrovirus. Subsequent to 7 days of hygromycin selection, cells were plated
for aphidicolin treatment. For each dose (0, 0.5 µM, and 1 µM) cells were plated
in triplicate in 6 well dishes. 24 hrs. later, media was exchanged for media
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containing the appropriate dose a aphidicolin. 24 hrs. later, cells (including
untreated cells) were washed once with warm PBS and grown in fresh media for
3-4 days until colonies were visible. Cells were washed with PBS and stained
with 50% MeOH, 7% glacial acetic acid, 0.1% Coomassie Brilliant Blue G for 10
min. Cells were rinsed with water and air-dried. Colonies were counted under a
light microscope.
Antibodies used
ID

antigen

Type

Applications
(h) human
(m) mouse

Origin

1254

mTRF2
(GST-FL)

Rb
poly

Western (m) 1:5000
ChIP (m) 1:70 (serum)

Celli/de
Lange

1252

mRap1
(GST-FL)

Rb
poly

Western (m) 1:10000
IF (m) 1:10,000
ChIP (m) 1:70 (serum)

Celli/de
Lange

644

mTRF1
(peptide)

Rb
poly

IF (m) 1:1000
ChIP (m) 1:350

Karlseder/de
Lange

1447

mTIN2
(GST-FL)

Rb
poly

IF (m) 1:2000
ChIP (m) 1:350

Donigian/de
lange

1151

mTPP1
(GST-250-544)

Rb
poly

ChIP (m) 1:350

Ye/de Lange

1220

mPot1a
(peptide)

Rb
poly

ChIP (m) 1:350

Hockemeyer/
de Lange lab

1223

mPot1b
(peptide)

Rb
poly

ChIP (m) 1:350

Hockemeyer/
de Lange lab

647

hTRF2
(baculoviral-FL)

Rb
poly

Western (h) 1:1000

Zhu/de
Lange lab

αhTRF2

hTRF2

Mo

Western (h) 1:1000

Upstate
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ID

antigen

Type

Applications
(h) human
(m) mouse

Origin

(peptide)

mono

αhTRF1

hTRF1
(baculoviral-FL)

Mo
poly

IF (h): 1:5000

Marrero/ de
Lange lab

9E10

c-myc peptide

Mo
mono

IF 1:5000

Sigma

9E10

c-myc peptide

Mo
mono

Western 1:1000

Calbiochem

M2

Flag peptide

Mo
mono

Western 1:10,000

Sigma

HA.11

HA peptide

Mo
mono

Western 1:1000

Covance

α53BP1

Human 53BP1

Mo
mono

IF (h,m) 1:50

Halazonetis,
The Wistar
Institute, PA

α53BP1

53BP1
(peptide)

Rb
poly

IF (m) 1:1000

Novus

α-γH2AX

γH2AX
(phospho
peptide S139)

Mo
mono

IF (h) 1:1000

Upstate

GTU88

γTubulin
(peptide)

Mo
mono

Western (h,m) 1:5000

Sigma

PG-M3

PML
(peptide)

Mo
mono

IF (h) 1:100

Santa Cruz

αATM-P

ATM (phospho
peptide S1981)

Mo
Mono

Western (h) 1:1000

Cell
Signaling

αChk1-P

Chk1-P
(phospho
peptide S345)

Rb
mono

Western (h,m) 1:1000

Cell
Signaling
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ID

antigen

Type

Applications
(h) human
(m) mouse

Origin

αp70 S6
kinase-P

p70 S6 kinase
(phospho
peptide T389)

Rb
mono

Western (h) 1:1000

Cell
Signaling

αTRF2
S368-P

TRF2 (phospho
peptide S368)

Rb
poly

Western (h) 1:1000
IF (h,m) 1:1000

AnaSpec/de
Lange

αTRF2
T188-P

TRF2 (phospho
peptide T188)

Rb
poly

IF (h,m) 1:200

AnaSpec/
Gilley

2G2

hMMS19

Mo

Western (h) 1:1000

Hoeijmakers,
Erasmus
Medical
Center, The
Netherlands

mono

FRP1(N19) ATR
1887

Gt
poly

Western (h) 1:500

Santa Cruz

MAT3

ATM

Mo
mono

Western (h) 1:6000

Sigma

DNAPK(C19)
1552

DNA-PK

Gt
poly

Western (h) 1:500

Santa Cruz

αSMG1

SMG1

Rb
poly

Western (h) 1:2000

Bethyl Labs

D16.11

ATM

M
mono

Immunoprecipitation

Alligood/
Glaxo

Rb: Rabbit; Mo: mouse; Gt: goat; poly: polyclonal; mono: monoclonal
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